organization · Reporting owner
EcoR1 Capital, LLC
Disclosed activity across 20 companies
Sign in to followReported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ANAPTYSBIO, INCANAB · Entity 4640 | Director · 10% owner | December 30, 2024 | January 02, 2025 |
| Aktis Oncology, Inc.AKTS · Entity 4711 | Director | January 12, 2026 | January 13, 2026 |
| Atara Biotherapeutics, Inc.ATRA · Entity 6828 | 10% owner | May 07, 2026 | May 11, 2026 |
| LENZ Therapeutics, Inc.GRPH · Entity 6475 | 10% owner | January 06, 2023 | January 07, 2023 |
| Mirati Therapeutics, Inc.MRTX · Entity 94908 | 10% owner | December 18, 2023 | December 27, 2023 |
| Nuvation Bio Inc.NUVB · Entity 4384 | Director | September 19, 2023 | September 22, 2023 |
| TScan Therapeutics, Inc.TCRX · Entity 7255 | 10% owner | May 26, 2023 | June 05, 2023 |
| Zymeworks Inc.ZYME · Entity 4458 | Director · 10% owner | June 26, 2025 | June 27, 2025 |
| iTeos Therapeutics, Inc.ITOS · Entity 75965 | 10% owner | May 14, 2025 | May 16, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ANAPTYSBIO, INC
Report date December 30, 2024 · Filed January 02, 2025
Jointly reported with NODELMAN OLEG
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectSee Note | 7,860,180 |
Reported balance
After 2024-12-30 transaction · row 1
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 1 · 2024-12-30 · Purchase · Acquired 65,184 · Balance 7,860,180 F2: Qualified Fund purchased all of the securities in this transaction. F3: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $12.71 to $12.9552, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnote 3. F4: After this transaction, Qualified Fund held 7,382,058 shares of the Issuer's Common Stock. F1: The reporting persons are EcoR1 Capital, LLC ("EcoR1"), Oleg Nodelman and EcoR1 Capital Fund Qualified L.P. ("Qualified Fund"). EcoR1 is the investment adviser and general partner of private funds, including Qualified Fund (collectively, the "Funds"). Mr. Nodelman is the manager and controlling owner of EcoR1 and a director of the Issuer. EcoR1 is filing this Form 4 for itself and Qualified Fund. The filers are filing this Form 4 jointly, but not as a group, and each expressly disclaims membership in a group within the meaning of Rule 13d-5(b) under the Securities Exchange Act of 1934. The Funds hold these securities directly for the benefit of their investors. EcoR1 may be deemed to indirectly beneficially own them as the investment adviser to the Funds. Mr. Nodelman may be deemed to indirectly beneficially own them as the control person of EcoR1. The filers disclaim beneficial ownership of such securities except to the extent of their pecuniary interests therein. |
| Common StockSEC Table I · non-derivative | IndirectSee Note | 7,873,448 |
Reported balance
After 2024-12-31 transaction · row 2
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 2 · 2024-12-31 · Purchase · Acquired 13,268 · Balance 7,873,448 F5: Qualified Fund purchased all of the securities in this transaction. F6: After this transaction, Qualified Fund held 7,395,326 shares of the Issuer's Common Stock. F1: The reporting persons are EcoR1 Capital, LLC ("EcoR1"), Oleg Nodelman and EcoR1 Capital Fund Qualified L.P. ("Qualified Fund"). EcoR1 is the investment adviser and general partner of private funds, including Qualified Fund (collectively, the "Funds"). Mr. Nodelman is the manager and controlling owner of EcoR1 and a director of the Issuer. EcoR1 is filing this Form 4 for itself and Qualified Fund. The filers are filing this Form 4 jointly, but not as a group, and each expressly disclaims membership in a group within the meaning of Rule 13d-5(b) under the Securities Exchange Act of 1934. The Funds hold these securities directly for the benefit of their investors. EcoR1 may be deemed to indirectly beneficially own them as the investment adviser to the Funds. Mr. Nodelman may be deemed to indirectly beneficially own them as the control person of EcoR1. The filers disclaim beneficial ownership of such securities except to the extent of their pecuniary interests therein. |
| Common StockSEC Table I · non-derivative | IndirectSee Note | 7,880,094 |
Reported balance
After 2025-01-02 transaction · row 3
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 3 · 2025-01-02 · Purchase · Acquired 6,646 · Balance 7,880,094 F7: Qualified Fund purchased all of the securities in this transaction. F8: After this transaction, Qualified Fund held 7,401,972 shares of the Issuer's Common Stock. F1: The reporting persons are EcoR1 Capital, LLC ("EcoR1"), Oleg Nodelman and EcoR1 Capital Fund Qualified L.P. ("Qualified Fund"). EcoR1 is the investment adviser and general partner of private funds, including Qualified Fund (collectively, the "Funds"). Mr. Nodelman is the manager and controlling owner of EcoR1 and a director of the Issuer. EcoR1 is filing this Form 4 for itself and Qualified Fund. The filers are filing this Form 4 jointly, but not as a group, and each expressly disclaims membership in a group within the meaning of Rule 13d-5(b) under the Securities Exchange Act of 1934. The Funds hold these securities directly for the benefit of their investors. EcoR1 may be deemed to indirectly beneficially own them as the investment adviser to the Funds. Mr. Nodelman may be deemed to indirectly beneficially own them as the control person of EcoR1. The filers disclaim beneficial ownership of such securities except to the extent of their pecuniary interests therein. |
Filing footnotes · ownership attribution and instrument terms
F1: The reporting persons are EcoR1 Capital, LLC ("EcoR1"), Oleg Nodelman and EcoR1 Capital Fund Qualified L.P. ("Qualified Fund"). EcoR1 is the investment adviser and general partner of private funds, including Qualified Fund (collectively, the "Funds"). Mr. Nodelman is the manager and controlling owner of EcoR1 and a director of the Issuer. EcoR1 is filing this Form 4 for itself and Qualified Fund. The filers are filing this Form 4 jointly, but not as a group, and each expressly disclaims membership in a group within the meaning of Rule 13d-5(b) under the Securities Exchange Act of 1934. The Funds hold these securities directly for the benefit of their investors. EcoR1 may be deemed to indirectly beneficially own them as the investment adviser to the Funds. Mr. Nodelman may be deemed to indirectly beneficially own them as the control person of EcoR1. The filers disclaim beneficial ownership of such securities except to the extent of their pecuniary interests therein.
F2: Qualified Fund purchased all of the securities in this transaction.
F3: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $12.71 to $12.9552, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnote 3.
F4: After this transaction, Qualified Fund held 7,382,058 shares of the Issuer's Common Stock.
F5: Qualified Fund purchased all of the securities in this transaction.
F6: After this transaction, Qualified Fund held 7,395,326 shares of the Issuer's Common Stock.
F7: Qualified Fund purchased all of the securities in this transaction.
F8: After this transaction, Qualified Fund held 7,401,972 shares of the Issuer's Common Stock.
Aktis Oncology, Inc.
Report date January 12, 2026 · Filed January 13, 2026
Jointly reported with NODELMAN OLEG
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectSee Note | 2,270,879 |
Reported balance
After 2026-01-12 transaction · row 1
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 1 · 2026-01-12 · Conversion · Acquired 2,270,879 · Balance 2,270,879 F1: The shares of Series A Redeemable Convertible Preferred Stock and Series B Redeemable Convertible Preferred Stock converted into shares of Common Stock and Class A Common Stock on a 3.8044-for-1 basis immediately prior to the closing of the initial public offering of the Issuer's Common Stock for no additional consideration. Each share was immediately exercisable and had no expiration date. F2: These securities are held by EcoR1 Capital Fund Qualified, L.P. ("Qualified Fund"). EcoR1 Capital, LLC ("EcoR1") may be deemed to indirectly beneficially own them as the investment adviser to and general partner of the fund. Mr. Nodelman may be deemed to indirectly beneficially own them as the control person of EcoR1. |
| Common StockSEC Table I · non-derivative | IndirectSee Note | 202,862 |
Reported balance
After 2026-01-12 transaction · row 2
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 2 · 2026-01-12 · Conversion · Acquired 202,862 · Balance 202,862 F1: The shares of Series A Redeemable Convertible Preferred Stock and Series B Redeemable Convertible Preferred Stock converted into shares of Common Stock and Class A Common Stock on a 3.8044-for-1 basis immediately prior to the closing of the initial public offering of the Issuer's Common Stock for no additional consideration. Each share was immediately exercisable and had no expiration date. F3: These securities are held by EcoR1 Capital Fund, L.P. ("Capital Fund"). EcoR1 may be deemed to indirectly beneficially own them as the investment adviser to and general partner of the fund. Mr. Nodelman may be deemed to indirectly beneficially own them as the control person of EcoR1. |
| Common StockSEC Table I · non-derivative | IndirectSee Note | 128,506 |
Reported balance
After 2026-01-12 transaction · row 3
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 3 · 2026-01-12 · Conversion · Acquired 128,506 · Balance 128,506 F1: The shares of Series A Redeemable Convertible Preferred Stock and Series B Redeemable Convertible Preferred Stock converted into shares of Common Stock and Class A Common Stock on a 3.8044-for-1 basis immediately prior to the closing of the initial public offering of the Issuer's Common Stock for no additional consideration. Each share was immediately exercisable and had no expiration date. F4: These securities are held by EcoR1 Venture Opportunity Fund, L.P. ("Venture Fund"). EcoR1 may be deemed to indirectly beneficially own them as the investment adviser to and general partner of the fund. Mr. Nodelman may be deemed to indirectly beneficially own them as the control person of EcoR1. |
| Common StockSEC Table I · non-derivative | IndirectSee Note | 4,348,658 |
Reported balance
After 2026-01-12 transaction · row 4
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 4 · 2026-01-12 · Purchase · Acquired 2,077,779 · Balance 4,348,658 F2: These securities are held by EcoR1 Capital Fund Qualified, L.P. ("Qualified Fund"). EcoR1 Capital, LLC ("EcoR1") may be deemed to indirectly beneficially own them as the investment adviser to and general partner of the fund. Mr. Nodelman may be deemed to indirectly beneficially own them as the control person of EcoR1. |
| Common StockSEC Table I · non-derivative | IndirectSee Note | 347,305 |
Reported balance
After 2026-01-12 transaction · row 5
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 5 · 2026-01-12 · Purchase · Acquired 144,443 · Balance 347,305 F3: These securities are held by EcoR1 Capital Fund, L.P. ("Capital Fund"). EcoR1 may be deemed to indirectly beneficially own them as the investment adviser to and general partner of the fund. Mr. Nodelman may be deemed to indirectly beneficially own them as the control person of EcoR1. |
| Series A Redeemable Convertible Preferred StockSEC Table II · derivative / convertible security | IndirectSee note | 0 |
Reported balance
After 2026-01-12 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2026-01-12 · Conversion · Disposed 9,913,810 · Balance 0 F1: The shares of Series A Redeemable Convertible Preferred Stock and Series B Redeemable Convertible Preferred Stock converted into shares of Common Stock and Class A Common Stock on a 3.8044-for-1 basis immediately prior to the closing of the initial public offering of the Issuer's Common Stock for no additional consideration. Each share was immediately exercisable and had no expiration date. F2: These securities are held by EcoR1 Capital Fund Qualified, L.P. ("Qualified Fund"). EcoR1 Capital, LLC ("EcoR1") may be deemed to indirectly beneficially own them as the investment adviser to and general partner of the fund. Mr. Nodelman may be deemed to indirectly beneficially own them as the control person of EcoR1. |
| Series A Redeemable Convertible Preferred StockSEC Table II · derivative / convertible security | IndirectSee note | 0 |
Reported balance
After 2026-01-12 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2026-01-12 · Conversion · Disposed 997,299 · Balance 0 F1: The shares of Series A Redeemable Convertible Preferred Stock and Series B Redeemable Convertible Preferred Stock converted into shares of Common Stock and Class A Common Stock on a 3.8044-for-1 basis immediately prior to the closing of the initial public offering of the Issuer's Common Stock for no additional consideration. Each share was immediately exercisable and had no expiration date. F3: These securities are held by EcoR1 Capital Fund, L.P. ("Capital Fund"). EcoR1 may be deemed to indirectly beneficially own them as the investment adviser to and general partner of the fund. Mr. Nodelman may be deemed to indirectly beneficially own them as the control person of EcoR1. |
| Series A Redeemable Convertible Preferred StockSEC Table II · derivative / convertible security | IndirectSee note | 0 |
Reported balance
After 2026-01-12 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2026-01-12 · Conversion · Disposed 488,891 · Balance 0 F1: The shares of Series A Redeemable Convertible Preferred Stock and Series B Redeemable Convertible Preferred Stock converted into shares of Common Stock and Class A Common Stock on a 3.8044-for-1 basis immediately prior to the closing of the initial public offering of the Issuer's Common Stock for no additional consideration. Each share was immediately exercisable and had no expiration date. F4: These securities are held by EcoR1 Venture Opportunity Fund, L.P. ("Venture Fund"). EcoR1 may be deemed to indirectly beneficially own them as the investment adviser to and general partner of the fund. Mr. Nodelman may be deemed to indirectly beneficially own them as the control person of EcoR1. |
| Series B Redeemable Convertible Preferred StockSEC Table II · derivative / convertible security | IndirectSee note | 0 |
Reported balance
After 2026-01-12 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2026-01-12 · Conversion · Disposed 2,397,500 · Balance 0 F1: The shares of Series A Redeemable Convertible Preferred Stock and Series B Redeemable Convertible Preferred Stock converted into shares of Common Stock and Class A Common Stock on a 3.8044-for-1 basis immediately prior to the closing of the initial public offering of the Issuer's Common Stock for no additional consideration. Each share was immediately exercisable and had no expiration date. F2: These securities are held by EcoR1 Capital Fund Qualified, L.P. ("Qualified Fund"). EcoR1 Capital, LLC ("EcoR1") may be deemed to indirectly beneficially own them as the investment adviser to and general partner of the fund. Mr. Nodelman may be deemed to indirectly beneficially own them as the control person of EcoR1. |
| Series B Redeemable Convertible Preferred StockSEC Table II · derivative / convertible security | IndirectSee note | 0 |
Reported balance
After 2026-01-12 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2026-01-12 · Conversion · Disposed 102,500 · Balance 0 F1: The shares of Series A Redeemable Convertible Preferred Stock and Series B Redeemable Convertible Preferred Stock converted into shares of Common Stock and Class A Common Stock on a 3.8044-for-1 basis immediately prior to the closing of the initial public offering of the Issuer's Common Stock for no additional consideration. Each share was immediately exercisable and had no expiration date. F3: These securities are held by EcoR1 Capital Fund, L.P. ("Capital Fund"). EcoR1 may be deemed to indirectly beneficially own them as the investment adviser to and general partner of the fund. Mr. Nodelman may be deemed to indirectly beneficially own them as the control person of EcoR1. |
| Class A Common StockSEC Table II · derivative / convertible security | IndirectSee note | 965,190 |
Reported balance
After 2026-01-12 transaction · row 11
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 11 · 2026-01-12 · Conversion · Acquired 965,190 · Balance 965,190 F5: Each share of Class A Common Stock is convertible into one share of Common Stock at the election of the holder for no additional consideration, subject to a 4.99% beneficial ownership limitation. Each share is immediately exercisable and has no expiration date. F1: The shares of Series A Redeemable Convertible Preferred Stock and Series B Redeemable Convertible Preferred Stock converted into shares of Common Stock and Class A Common Stock on a 3.8044-for-1 basis immediately prior to the closing of the initial public offering of the Issuer's Common Stock for no additional consideration. Each share was immediately exercisable and had no expiration date. F2: These securities are held by EcoR1 Capital Fund Qualified, L.P. ("Qualified Fund"). EcoR1 Capital, LLC ("EcoR1") may be deemed to indirectly beneficially own them as the investment adviser to and general partner of the fund. Mr. Nodelman may be deemed to indirectly beneficially own them as the control person of EcoR1. |
| Class A Common StockSEC Table II · derivative / convertible security | IndirectSee Note | 86,222 |
Reported balance
After 2026-01-12 transaction · row 12
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 12 · 2026-01-12 · Conversion · Acquired 86,222 · Balance 86,222 F5: Each share of Class A Common Stock is convertible into one share of Common Stock at the election of the holder for no additional consideration, subject to a 4.99% beneficial ownership limitation. Each share is immediately exercisable and has no expiration date. F1: The shares of Series A Redeemable Convertible Preferred Stock and Series B Redeemable Convertible Preferred Stock converted into shares of Common Stock and Class A Common Stock on a 3.8044-for-1 basis immediately prior to the closing of the initial public offering of the Issuer's Common Stock for no additional consideration. Each share was immediately exercisable and had no expiration date. F3: These securities are held by EcoR1 Capital Fund, L.P. ("Capital Fund"). EcoR1 may be deemed to indirectly beneficially own them as the investment adviser to and general partner of the fund. Mr. Nodelman may be deemed to indirectly beneficially own them as the control person of EcoR1. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares of Series A Redeemable Convertible Preferred Stock and Series B Redeemable Convertible Preferred Stock converted into shares of Common Stock and Class A Common Stock on a 3.8044-for-1 basis immediately prior to the closing of the initial public offering of the Issuer's Common Stock for no additional consideration. Each share was immediately exercisable and had no expiration date.
F2: These securities are held by EcoR1 Capital Fund Qualified, L.P. ("Qualified Fund"). EcoR1 Capital, LLC ("EcoR1") may be deemed to indirectly beneficially own them as the investment adviser to and general partner of the fund. Mr. Nodelman may be deemed to indirectly beneficially own them as the control person of EcoR1.
F3: These securities are held by EcoR1 Capital Fund, L.P. ("Capital Fund"). EcoR1 may be deemed to indirectly beneficially own them as the investment adviser to and general partner of the fund. Mr. Nodelman may be deemed to indirectly beneficially own them as the control person of EcoR1.
F4: These securities are held by EcoR1 Venture Opportunity Fund, L.P. ("Venture Fund"). EcoR1 may be deemed to indirectly beneficially own them as the investment adviser to and general partner of the fund. Mr. Nodelman may be deemed to indirectly beneficially own them as the control person of EcoR1.
F5: Each share of Class A Common Stock is convertible into one share of Common Stock at the election of the holder for no additional consideration, subject to a 4.99% beneficial ownership limitation. Each share is immediately exercisable and has no expiration date.
Atara Biotherapeutics, Inc.
Report date May 07, 2026 · Filed May 11, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectSee Note | 1,552,000 |
Reported balance
After 2026-05-07 transaction · row 1
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 1 · 2026-05-07 · Purchase · Acquired 507,407 · Balance 1,552,000 F2: Qualified Fund purchased 474,780 of the shares puchased in this transaction. F3: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $8.85 to $9.39 inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote. F4: After this transaction, Qualified Fund held 1,445,609 shares of the Issuer's Common Stock. F1: The reporting persons are EcoR1 Capital, LLC ("EcoR1"), Oleg Nodelman and EcoR1 Capital Fund Qualified, L.P. ("Qualified Fund"). EcoR1 is the general partner and investment adviser of private funds, including Qualified Fund (the "Funds"). Mr. Nodelman is the manager and controller owner of EcoR1. EcoR1 is filing this Form 4 for itself, Mr. Nodelman and Qualified Fund. The reporting persons are filing this Form 4 jointly, but not as a group, and each expressly disclaims membership in a group within the meaning of Rule 13d-5(b) under the Securities Exchange Act of 1934. The Funds hold these securities directly for the benefit of their investors. EcoR1 may be deemed to indirectly beneficially own them as the investment adviser to the Funds. Mr. Nodelman may be deemed to indirectly beneficially own them as the control person of EcoR1. The reporting persons disclaim beneficial ownership of the securities except to the extent of their respective pecuniary interests therein. |
Filing footnotes · ownership attribution and instrument terms
F1: The reporting persons are EcoR1 Capital, LLC ("EcoR1"), Oleg Nodelman and EcoR1 Capital Fund Qualified, L.P. ("Qualified Fund"). EcoR1 is the general partner and investment adviser of private funds, including Qualified Fund (the "Funds"). Mr. Nodelman is the manager and controller owner of EcoR1. EcoR1 is filing this Form 4 for itself, Mr. Nodelman and Qualified Fund. The reporting persons are filing this Form 4 jointly, but not as a group, and each expressly disclaims membership in a group within the meaning of Rule 13d-5(b) under the Securities Exchange Act of 1934. The Funds hold these securities directly for the benefit of their investors. EcoR1 may be deemed to indirectly beneficially own them as the investment adviser to the Funds. Mr. Nodelman may be deemed to indirectly beneficially own them as the control person of EcoR1. The reporting persons disclaim beneficial ownership of the securities except to the extent of their respective pecuniary interests therein.
F2: Qualified Fund purchased 474,780 of the shares puchased in this transaction.
F3: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $8.85 to $9.39 inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote.
F4: After this transaction, Qualified Fund held 1,445,609 shares of the Issuer's Common Stock.
LENZ Therapeutics, Inc.
Report date January 06, 2023 · Filed January 07, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectSee Notes 1 and 2 | 8,538,446 |
Reported balance
Holding disclosure · report date 2023-01-06 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 8,538,446 F1: The filing persons (the "Filers") are EcoR1 Capital, LLC ("EcoR1"), Oleg Nodelman and EcoR1 Capital Fund Qualified, L.P. ("Qualified Fund"). EcoR1 is the general partner and investment adviser of private funds, including Qualified Fund (collectively, the "Funds"). Mr. Nodelman is the manager and controlling owner of EcoR1. EcoR1 is filing this Form 3 for itself, Mr. Nodelman and Qualified Fund. The Filers are filing this Form 3 jointly, but not as a group, and each expressly disclaims membership in a group, within the meaning of Rule 13d-5(b) under the Securities Exchange Act of 1934, as amended. The Funds hold these securities directly for the benefit of their investors. EcoR1 indirectly beneficially owns them as the investment adviser to the Funds, and Mr. Nodelman indirectly beneficially owns them as the control person of EcoR1. The Filers disclaim beneficial ownership of such securities except to the extent of their respective pecuniary interests therein. F2: Qualified Fund directly holds 8,039,801 of the shares of Common Stock reported in this Form 3. |
Filing footnotes · ownership attribution and instrument terms
F1: The filing persons (the "Filers") are EcoR1 Capital, LLC ("EcoR1"), Oleg Nodelman and EcoR1 Capital Fund Qualified, L.P. ("Qualified Fund"). EcoR1 is the general partner and investment adviser of private funds, including Qualified Fund (collectively, the "Funds"). Mr. Nodelman is the manager and controlling owner of EcoR1. EcoR1 is filing this Form 3 for itself, Mr. Nodelman and Qualified Fund. The Filers are filing this Form 3 jointly, but not as a group, and each expressly disclaims membership in a group, within the meaning of Rule 13d-5(b) under the Securities Exchange Act of 1934, as amended. The Funds hold these securities directly for the benefit of their investors. EcoR1 indirectly beneficially owns them as the investment adviser to the Funds, and Mr. Nodelman indirectly beneficially owns them as the control person of EcoR1. The Filers disclaim beneficial ownership of such securities except to the extent of their respective pecuniary interests therein.
F2: Qualified Fund directly holds 8,039,801 of the shares of Common Stock reported in this Form 3.
Mirati Therapeutics, Inc.
Report date December 18, 2023 · Filed December 27, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectSee Note | 7,396,979 |
Reported balance
Holding disclosure · report date 2023-12-18 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 7,396,979 F1: The filing persons (the "Filers") are EcoR1 Capital, LLC ("EcoR1") and Oleg Nodelman. EcoR1 is the general partner and investment adviser of private funds (collectively, the "Funds"). Mr. Nodelman is the manager and controlling owner of EcoR1. EcoR1 is filing this Form 3 for itself and Mr. Nodelman. The Filers are filing this Form 3 jointly, but not as a group, and each expressly disclaims membership in a group, within the meaning of Rule 13d-5(b) under the Securities Exchange Act of 1934, as amended. The Funds hold these securities directly for the benefit of their investors. EcoR1 indirectly beneficially owns them as the investment adviser to the Funds, and Mr. Nodelman indirectly beneficially owns them as the control person of EcoR1. The Filers disclaim beneficial ownership of such securities except to the extent of their respective pecuniary interests therein. |
Filing footnotes · ownership attribution and instrument terms
F1: The filing persons (the "Filers") are EcoR1 Capital, LLC ("EcoR1") and Oleg Nodelman. EcoR1 is the general partner and investment adviser of private funds (collectively, the "Funds"). Mr. Nodelman is the manager and controlling owner of EcoR1. EcoR1 is filing this Form 3 for itself and Mr. Nodelman. The Filers are filing this Form 3 jointly, but not as a group, and each expressly disclaims membership in a group, within the meaning of Rule 13d-5(b) under the Securities Exchange Act of 1934, as amended. The Funds hold these securities directly for the benefit of their investors. EcoR1 indirectly beneficially owns them as the investment adviser to the Funds, and Mr. Nodelman indirectly beneficially owns them as the control person of EcoR1. The Filers disclaim beneficial ownership of such securities except to the extent of their respective pecuniary interests therein.
Nuvation Bio Inc.
Report date September 19, 2023 · Filed September 22, 2023 · Amendment
Jointly reported with NODELMAN OLEG, EcoR1 Capital Fund, L.P., EcoR1 Capital Fund Qualified, L.P., EcoR1 Venture Opportunity Fund, LP, Biotech Opportunity GP, LLC
Amendment: balances below belong to this corrected disclosure, not necessarily a complete replacement of earlier positions.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A Common StockSEC Table I · non-derivative | IndirectSee Notes | 12,674,775 |
Last balance in matching sequence
After 2023-09-21 transaction · row 3
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
3 source rowsRow 1 · 2023-09-19 · Purchase · Acquired 5,143,000 · Balance 12,504,675 F3: On 9/21/2023, the reporting persons filed a Form 4 (the "Original Form 4") that inadvertently identified the date of this transaction as 2/19/2023. As reported in this amendment, the date of this transaction was 9/19/2023. The Original Form 4 also inadvertently identified the date of the earliest transaction reported in the Original Form 4 as 2/19/2023. As reported in this amendment, the date of the earliest transaction was 9/19/2023. F1: EcoR1 Capital, LLC ("EcoR1") is the investment adviser to EcoR1 Capital Fund, L.P. ("Capital Fund"), EcoR1 Capital Fund Qualified, L.P. ("Qualified Fund") and EcoR1 Venture Opportunity Fund, L.P. ("Venture Fund"). EcoR1 is the general partner of Capital Fund and Qualified Fund, and Biotech Opportunity GP, LLC ("Biotech") is the general partner of Venture Fund. Mr. Nodelman is the manager and controlling owner of EcoR1 and Biotech. The funds hold these securities directly for the benefit of their investors. EcoR1 indirectly beneficially owns them as the investment adviser to the funds. Mr. Nodelman indirectly beneficially owns them as the control person of EcoR1. The reporting persons disclaim beneficial ownership of such securities except to the extent of their pecuniary interest therein. F2: Qualified Fund is the record holder of these securities. Row 2 · 2023-09-20 · Purchase · Acquired 117,100 · Balance 12,621,775 F4: The Original Form 4 inadvertently identified the date of this transaction as 2/20/2023. As reported in this amendment, the date of this transaction was 9/20/2023. F1: EcoR1 Capital, LLC ("EcoR1") is the investment adviser to EcoR1 Capital Fund, L.P. ("Capital Fund"), EcoR1 Capital Fund Qualified, L.P. ("Qualified Fund") and EcoR1 Venture Opportunity Fund, L.P. ("Venture Fund"). EcoR1 is the general partner of Capital Fund and Qualified Fund, and Biotech Opportunity GP, LLC ("Biotech") is the general partner of Venture Fund. Mr. Nodelman is the manager and controlling owner of EcoR1 and Biotech. The funds hold these securities directly for the benefit of their investors. EcoR1 indirectly beneficially owns them as the investment adviser to the funds. Mr. Nodelman indirectly beneficially owns them as the control person of EcoR1. The reporting persons disclaim beneficial ownership of such securities except to the extent of their pecuniary interest therein. F2: Qualified Fund is the record holder of these securities. Row 3 · 2023-09-21 · Purchase · Acquired 53,000 · Balance 12,674,775 F5: Original Form 4 inadvertently identified the date of this transaction as 2/21/2023. As reported in this amendment, the date of this transaction was 9/21/2023. F1: EcoR1 Capital, LLC ("EcoR1") is the investment adviser to EcoR1 Capital Fund, L.P. ("Capital Fund"), EcoR1 Capital Fund Qualified, L.P. ("Qualified Fund") and EcoR1 Venture Opportunity Fund, L.P. ("Venture Fund"). EcoR1 is the general partner of Capital Fund and Qualified Fund, and Biotech Opportunity GP, LLC ("Biotech") is the general partner of Venture Fund. Mr. Nodelman is the manager and controlling owner of EcoR1 and Biotech. The funds hold these securities directly for the benefit of their investors. EcoR1 indirectly beneficially owns them as the investment adviser to the funds. Mr. Nodelman indirectly beneficially owns them as the control person of EcoR1. The reporting persons disclaim beneficial ownership of such securities except to the extent of their pecuniary interest therein. F2: Qualified Fund is the record holder of these securities. |
Filing footnotes · ownership attribution and instrument terms
F1: EcoR1 Capital, LLC ("EcoR1") is the investment adviser to EcoR1 Capital Fund, L.P. ("Capital Fund"), EcoR1 Capital Fund Qualified, L.P. ("Qualified Fund") and EcoR1 Venture Opportunity Fund, L.P. ("Venture Fund"). EcoR1 is the general partner of Capital Fund and Qualified Fund, and Biotech Opportunity GP, LLC ("Biotech") is the general partner of Venture Fund. Mr. Nodelman is the manager and controlling owner of EcoR1 and Biotech. The funds hold these securities directly for the benefit of their investors. EcoR1 indirectly beneficially owns them as the investment adviser to the funds. Mr. Nodelman indirectly beneficially owns them as the control person of EcoR1. The reporting persons disclaim beneficial ownership of such securities except to the extent of their pecuniary interest therein.
F2: Qualified Fund is the record holder of these securities.
F3: On 9/21/2023, the reporting persons filed a Form 4 (the "Original Form 4") that inadvertently identified the date of this transaction as 2/19/2023. As reported in this amendment, the date of this transaction was 9/19/2023. The Original Form 4 also inadvertently identified the date of the earliest transaction reported in the Original Form 4 as 2/19/2023. As reported in this amendment, the date of the earliest transaction was 9/19/2023.
F4: The Original Form 4 inadvertently identified the date of this transaction as 2/20/2023. As reported in this amendment, the date of this transaction was 9/20/2023.
F5: Original Form 4 inadvertently identified the date of this transaction as 2/21/2023. As reported in this amendment, the date of this transaction was 9/21/2023.
TScan Therapeutics, Inc.
Report date May 26, 2023 · Filed June 05, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Voting Common StockSEC Table I · non-derivative | IndirectSee Notes 1 and 2 | 5,000,000 |
Reported balance
Holding disclosure · report date 2023-05-26 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 5,000,000 F1: The filing persons (the "Filers") are EcoR1 Capital, LLC ("EcoR1"), Oleg Nodelman and EcoR1 Capital Fund Qualified, L.P. ("Qualified Fund"). EcoR1 is the general partner and investment adviser of private funds, including Qualified Fund (collectively, the "Funds"). Mr. Nodelman is the manager and controlling owner of EcoR1. EcoR1 is filing this Form 3 for itself, Mr. Nodelman and Qualified Fund. The Filers are filing this Form 3 jointly, but not as a group, and each expressly disclaims membership in a group, within the meaning of Rule 13d-5(b) under the Securities Exchange Act of 1934, as amended. The Funds hold these securities directly for the benefit of their investors. EcoR1 indirectly beneficially owns them as the investment adviser to the Funds, and Mr. Nodelman indirectly beneficially owns them as the control person of EcoR1. The Filers disclaim beneficial ownership of such ecurities except to the extent of their respective pecuniary interests therein. F2: Qualified Fund directly holds 4,640,415 of the shares of Voting Common Stock reported in this Form 3. |
Filing footnotes · ownership attribution and instrument terms
F1: The filing persons (the "Filers") are EcoR1 Capital, LLC ("EcoR1"), Oleg Nodelman and EcoR1 Capital Fund Qualified, L.P. ("Qualified Fund"). EcoR1 is the general partner and investment adviser of private funds, including Qualified Fund (collectively, the "Funds"). Mr. Nodelman is the manager and controlling owner of EcoR1. EcoR1 is filing this Form 3 for itself, Mr. Nodelman and Qualified Fund. The Filers are filing this Form 3 jointly, but not as a group, and each expressly disclaims membership in a group, within the meaning of Rule 13d-5(b) under the Securities Exchange Act of 1934, as amended. The Funds hold these securities directly for the benefit of their investors. EcoR1 indirectly beneficially owns them as the investment adviser to the Funds, and Mr. Nodelman indirectly beneficially owns them as the control person of EcoR1. The Filers disclaim beneficial ownership of such ecurities except to the extent of their respective pecuniary interests therein.
F2: Qualified Fund directly holds 4,640,415 of the shares of Voting Common Stock reported in this Form 3.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectSee Note | 22,970,388 |
Reported balance
After 2025-06-26 transaction · row 1
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 1 · 2025-06-26 · Other · Acquired 5,086,480 · Balance 22,970,388 F2: Qualified Fund acquired 4,818,424 shares of Common Stock in connection with the exercise of the pre-funded warrants. F3: After the transactions reported herein, Qualified Fund held 21,582,563 shares of the Issuer's Common Stock. F1: The reporting persons are EcoR1 Capital, LLC ("EcoR1"), Oleg Nodelman and EcoR1 Capital Fund Qualified, L.P. ("Qualified Fund"). EcoR1 is the general partner and investment adviser of private funds, including Qualified Fund (the "Funds"). Mr. Nodelman is the manager and controlling owner of EcoR1. EcoR1 is filing this Form 4 for itself and Qualified Fund. The filers are filing this Form 4 jointly, but not as a group, and each expressly disclaims membership in a group within the meaning of Rule 13d-5(b) under the Securities Exchange Act of 1934. The Funds hold these securities directly for the benefit of their investors. EcoR1 may be deemed to indirectly beneficially own them as the investment adviser to the Funds. Mr. Nodelman may be deemed to indirectly beneficially own them as the control person of EcoR1. The filers disclaim beneficial ownership of the securities except to the extent of their respective pecuniary interests therein. |
| Common StockSEC Table I · non-derivative | IndirectSee Note | 22,970,388 |
Reported balance
After 2025-06-26 transaction · row 2
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 2 · 2025-06-26 · Tax withholding · Disposed 41 · Balance 22,970,388 F4: On June 26, 2025,the reporting persons exercised pre-funded warrants to purchase 5,086,521 shares of the Issuer's Common Stock for $0.0001 per share. The reporting persons paid the exercise price on a cashless basis, resulting in the Issuer withholding 41 of the warrant shares (including 38 warrant shares issuable to Qualified Fund) to pay the exercise price and issuing to the reporting persons the remaining 5,086,480 shares. F3: After the transactions reported herein, Qualified Fund held 21,582,563 shares of the Issuer's Common Stock. F1: The reporting persons are EcoR1 Capital, LLC ("EcoR1"), Oleg Nodelman and EcoR1 Capital Fund Qualified, L.P. ("Qualified Fund"). EcoR1 is the general partner and investment adviser of private funds, including Qualified Fund (the "Funds"). Mr. Nodelman is the manager and controlling owner of EcoR1. EcoR1 is filing this Form 4 for itself and Qualified Fund. The filers are filing this Form 4 jointly, but not as a group, and each expressly disclaims membership in a group within the meaning of Rule 13d-5(b) under the Securities Exchange Act of 1934. The Funds hold these securities directly for the benefit of their investors. EcoR1 may be deemed to indirectly beneficially own them as the investment adviser to the Funds. Mr. Nodelman may be deemed to indirectly beneficially own them as the control person of EcoR1. The filers disclaim beneficial ownership of the securities except to the extent of their respective pecuniary interests therein. |
| Pre-Funded Warrants (right to acquire)SEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | IndirectSee note | 0 |
Reported balance
After 2025-06-26 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2025-06-26 · Other · Disposed 5,086,521 · Balance 0 F5: Qualified Fund exercised 4,818,462 of the pre-funded warrants reported in this transaction. F6: The pre-funded warrants did not have an expiration date. F1: The reporting persons are EcoR1 Capital, LLC ("EcoR1"), Oleg Nodelman and EcoR1 Capital Fund Qualified, L.P. ("Qualified Fund"). EcoR1 is the general partner and investment adviser of private funds, including Qualified Fund (the "Funds"). Mr. Nodelman is the manager and controlling owner of EcoR1. EcoR1 is filing this Form 4 for itself and Qualified Fund. The filers are filing this Form 4 jointly, but not as a group, and each expressly disclaims membership in a group within the meaning of Rule 13d-5(b) under the Securities Exchange Act of 1934. The Funds hold these securities directly for the benefit of their investors. EcoR1 may be deemed to indirectly beneficially own them as the investment adviser to the Funds. Mr. Nodelman may be deemed to indirectly beneficially own them as the control person of EcoR1. The filers disclaim beneficial ownership of the securities except to the extent of their respective pecuniary interests therein. |
Filing footnotes · ownership attribution and instrument terms
F1: The reporting persons are EcoR1 Capital, LLC ("EcoR1"), Oleg Nodelman and EcoR1 Capital Fund Qualified, L.P. ("Qualified Fund"). EcoR1 is the general partner and investment adviser of private funds, including Qualified Fund (the "Funds"). Mr. Nodelman is the manager and controlling owner of EcoR1. EcoR1 is filing this Form 4 for itself and Qualified Fund. The filers are filing this Form 4 jointly, but not as a group, and each expressly disclaims membership in a group within the meaning of Rule 13d-5(b) under the Securities Exchange Act of 1934. The Funds hold these securities directly for the benefit of their investors. EcoR1 may be deemed to indirectly beneficially own them as the investment adviser to the Funds. Mr. Nodelman may be deemed to indirectly beneficially own them as the control person of EcoR1. The filers disclaim beneficial ownership of the securities except to the extent of their respective pecuniary interests therein.
F2: Qualified Fund acquired 4,818,424 shares of Common Stock in connection with the exercise of the pre-funded warrants.
F3: After the transactions reported herein, Qualified Fund held 21,582,563 shares of the Issuer's Common Stock.
F4: On June 26, 2025,the reporting persons exercised pre-funded warrants to purchase 5,086,521 shares of the Issuer's Common Stock for $0.0001 per share. The reporting persons paid the exercise price on a cashless basis, resulting in the Issuer withholding 41 of the warrant shares (including 38 warrant shares issuable to Qualified Fund) to pay the exercise price and issuing to the reporting persons the remaining 5,086,480 shares.
F5: Qualified Fund exercised 4,818,462 of the pre-funded warrants reported in this transaction.
F6: The pre-funded warrants did not have an expiration date.
iTeos Therapeutics, Inc.
Report date May 14, 2025 · Filed May 16, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectSee Note | 7,388,978 |
Reported balance
After 2025-05-14 transaction · row 1
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 1 · 2025-05-14 · Purchase · Acquired 1,658,978 · Balance 7,388,978 F2: Qualified Fund purchased 1,555,127 of the shares purchased in this transaction. F3: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $7.35 to $7.60, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote. F4: After this transaction, Qualified Fund held 6,926,788 shares of the Issuer's Common Stock. F1: The reporting persons are EcoR1 Capital, LLC ("Ecor1"), Oleg Nodelman and EcoR1 Capital Fund Qualified, L.P. ("Qualified Fund"). EcoR1 is the general partner and investment adviser of private funds, including Qualified Fund (the "Funds"). Mr. Nodelman is the manager and controlling owner of EcoR1. EcoR1 is filing this Form 4 for itself, Mr. Nodelman and Qualified Fund. The filers are filing this Form 4 jointly, but not as a group, and each expressly disclaims membership in a group within the meaning of Rule 13d-5(b) under the Securities Exchange Act of 1934. The Funds hold these securities directly for the benefit of their investors. EcoR1 may be deemed to indirectly beneficially own them as the investment adviser to the Funds. Mr. Nodelman may be deemed to indirectly beneficially own them as the control person of EcoR1. The filers disclaim beneficial ownership of the securities except to the extent of their respective pecuniary interests therein. |
| Common StockSEC Table I · non-derivative | IndirectSee Note | 10,688,978 |
Reported balance
After 2025-05-15 transaction · row 2
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 2 · 2025-05-15 · Purchase · Acquired 3,300,000 · Balance 10,688,978 F5: Qualified Fund purchased 3,093,422 of the shares purchased in this transaction. F6: After this transaction, Qualified Fund held 10,020,210 shares of the Issuer's Common Stock. F1: The reporting persons are EcoR1 Capital, LLC ("Ecor1"), Oleg Nodelman and EcoR1 Capital Fund Qualified, L.P. ("Qualified Fund"). EcoR1 is the general partner and investment adviser of private funds, including Qualified Fund (the "Funds"). Mr. Nodelman is the manager and controlling owner of EcoR1. EcoR1 is filing this Form 4 for itself, Mr. Nodelman and Qualified Fund. The filers are filing this Form 4 jointly, but not as a group, and each expressly disclaims membership in a group within the meaning of Rule 13d-5(b) under the Securities Exchange Act of 1934. The Funds hold these securities directly for the benefit of their investors. EcoR1 may be deemed to indirectly beneficially own them as the investment adviser to the Funds. Mr. Nodelman may be deemed to indirectly beneficially own them as the control person of EcoR1. The filers disclaim beneficial ownership of the securities except to the extent of their respective pecuniary interests therein. |
Filing footnotes · ownership attribution and instrument terms
F1: The reporting persons are EcoR1 Capital, LLC ("Ecor1"), Oleg Nodelman and EcoR1 Capital Fund Qualified, L.P. ("Qualified Fund"). EcoR1 is the general partner and investment adviser of private funds, including Qualified Fund (the "Funds"). Mr. Nodelman is the manager and controlling owner of EcoR1. EcoR1 is filing this Form 4 for itself, Mr. Nodelman and Qualified Fund. The filers are filing this Form 4 jointly, but not as a group, and each expressly disclaims membership in a group within the meaning of Rule 13d-5(b) under the Securities Exchange Act of 1934. The Funds hold these securities directly for the benefit of their investors. EcoR1 may be deemed to indirectly beneficially own them as the investment adviser to the Funds. Mr. Nodelman may be deemed to indirectly beneficially own them as the control person of EcoR1. The filers disclaim beneficial ownership of the securities except to the extent of their respective pecuniary interests therein.
F2: Qualified Fund purchased 1,555,127 of the shares purchased in this transaction.
F3: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $7.35 to $7.60, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote.
F4: After this transaction, Qualified Fund held 6,926,788 shares of the Issuer's Common Stock.
F5: Qualified Fund purchased 3,093,422 of the shares purchased in this transaction.
F6: After this transaction, Qualified Fund held 10,020,210 shares of the Issuer's Common Stock.
Past disclosures · reporting ended (11)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Adaptimmune Therapeutics PLC
Report date July 28, 2025 · Filed July 30, 2025
Section 16 reporting ended · disclosed 2025-07-30. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | IndirectSee Note | 130,492,680 |
Reported balance
After 2025-07-28 transaction · row 1
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 1 · 2025-07-28 · Sale · Disposed 33,931,740 · Balance 130,492,680 F1: These Ordinary Shares are held through American Depositary Shares ("ADS") of the Issuer. Each ADS represents 6 Ordinary Shares. F3: The reporting persons sold 5,655,290 ADSs representing 33,931,740 Ordinary Shares. Qualified Fund sold 5,281,476 of those ADSs, representing 31,688,856 Ordinary Shares. F4: The price reported in Column 4 is the price per ADS sold by the reporting persons. This price is a weighted average price. These ADSs were sold in multiple transactions at prices ranging from $0.1086 to $0.1184, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of ADSs sold at each separate price within the ranges set forth in this footnote. F5: After this transaction, the reporting persons beneficially owned 21,748,780 ADSs, including 20,569,634 ADS held by Qualified Fund representing 123,417,804 Ordinary Shares. F2: The reporting persons are EcoR1 Capital, LLC ("Ecor1"), Oleg Nodelman and EcoR1 Capital Fund Qualified, L.P. ("Qualified Fund"). EcoR1 is the general partner and investment adviser of private funds, including Qualified Fund (the "Fund"). Mr. Nodelman is the manager and controlling owner of EcoR1. EcoR1 is filing this Form 4 for itself, Mr. Nodelman and Qualified Fund. The filers are filing this Form 4 jointly, but not as a group, and each expressly disclaims membership in a group within the meaning of Rule 13d-5(b) under the Securities Exchange Act of 1934. The Funds hold these securities directly for the benefit of their investors. EcoR1 may be deemed to indirectly beneficially own them as the investment adviser to the Funds. Mr. Nodelman may be deemed to indirectly beneficially own them as the control person of EcoR1. The filers disclaim beneficial ownership of the securities except to the extent of their respective pecuniary interests therein. |
| Ordinary SharesSEC Table I · non-derivative | IndirectSee Note | 127,805,220 |
Reported balance
After 2025-07-29 transaction · row 2
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 2 · 2025-07-29 · Sale · Disposed 2,687,460 · Balance 127,805,220 F1: These Ordinary Shares are held through American Depositary Shares ("ADS") of the Issuer. Each ADS represents 6 Ordinary Shares. F6: The reporting persons sold 447,910 ADSs representing 2,687,460 Ordinary Shares. Qualified Fund sold 418,303 of those ADSs, representing 2,509,818 Ordinary Shares. F7: The price reported in Column 4 is the price per ADS sold by the reporting persons. F8: After this transaction, the reporting persons beneficially owned 21,300,870 ADSs, including 20,151,331 ADSs held by Qualified Fund representing 120,907,986 Ordinary Shares. F2: The reporting persons are EcoR1 Capital, LLC ("Ecor1"), Oleg Nodelman and EcoR1 Capital Fund Qualified, L.P. ("Qualified Fund"). EcoR1 is the general partner and investment adviser of private funds, including Qualified Fund (the "Fund"). Mr. Nodelman is the manager and controlling owner of EcoR1. EcoR1 is filing this Form 4 for itself, Mr. Nodelman and Qualified Fund. The filers are filing this Form 4 jointly, but not as a group, and each expressly disclaims membership in a group within the meaning of Rule 13d-5(b) under the Securities Exchange Act of 1934. The Funds hold these securities directly for the benefit of their investors. EcoR1 may be deemed to indirectly beneficially own them as the investment adviser to the Funds. Mr. Nodelman may be deemed to indirectly beneficially own them as the control person of EcoR1. The filers disclaim beneficial ownership of the securities except to the extent of their respective pecuniary interests therein. |
| Ordinary SharesSEC Table I · non-derivative | IndirectSee Note | 100,371,882 |
Reported balance
After 2025-07-30 transaction · row 3
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 3 · 2025-07-30 · Sale · Disposed 27,433,338 · Balance 100,371,882 F1: These Ordinary Shares are held through American Depositary Shares ("ADS") of the Issuer. Each ADS represents 6 Ordinary Shares. F9: The reporting persons sold 4,572,223 ADSs representing 27,433,338 Ordinary Shares. Qualified Fund sold 4,270,000 of those ADSs, representing 25,620,000 Ordinary Shares. F7: The price reported in Column 4 is the price per ADS sold by the reporting persons. F10: After this transaction, the reporting persons beneficially owned 16,728,647 ADSs, including 15,881,331 ADSs held by Qualified Fund representing 95,287,986 Ordinary Shares. F2: The reporting persons are EcoR1 Capital, LLC ("Ecor1"), Oleg Nodelman and EcoR1 Capital Fund Qualified, L.P. ("Qualified Fund"). EcoR1 is the general partner and investment adviser of private funds, including Qualified Fund (the "Fund"). Mr. Nodelman is the manager and controlling owner of EcoR1. EcoR1 is filing this Form 4 for itself, Mr. Nodelman and Qualified Fund. The filers are filing this Form 4 jointly, but not as a group, and each expressly disclaims membership in a group within the meaning of Rule 13d-5(b) under the Securities Exchange Act of 1934. The Funds hold these securities directly for the benefit of their investors. EcoR1 may be deemed to indirectly beneficially own them as the investment adviser to the Funds. Mr. Nodelman may be deemed to indirectly beneficially own them as the control person of EcoR1. The filers disclaim beneficial ownership of the securities except to the extent of their respective pecuniary interests therein. |
Filing footnotes · ownership attribution and instrument terms
F1: These Ordinary Shares are held through American Depositary Shares ("ADS") of the Issuer. Each ADS represents 6 Ordinary Shares.
F2: The reporting persons are EcoR1 Capital, LLC ("Ecor1"), Oleg Nodelman and EcoR1 Capital Fund Qualified, L.P. ("Qualified Fund"). EcoR1 is the general partner and investment adviser of private funds, including Qualified Fund (the "Fund"). Mr. Nodelman is the manager and controlling owner of EcoR1. EcoR1 is filing this Form 4 for itself, Mr. Nodelman and Qualified Fund. The filers are filing this Form 4 jointly, but not as a group, and each expressly disclaims membership in a group within the meaning of Rule 13d-5(b) under the Securities Exchange Act of 1934. The Funds hold these securities directly for the benefit of their investors. EcoR1 may be deemed to indirectly beneficially own them as the investment adviser to the Funds. Mr. Nodelman may be deemed to indirectly beneficially own them as the control person of EcoR1. The filers disclaim beneficial ownership of the securities except to the extent of their respective pecuniary interests therein.
F3: The reporting persons sold 5,655,290 ADSs representing 33,931,740 Ordinary Shares. Qualified Fund sold 5,281,476 of those ADSs, representing 31,688,856 Ordinary Shares.
F4: The price reported in Column 4 is the price per ADS sold by the reporting persons. This price is a weighted average price. These ADSs were sold in multiple transactions at prices ranging from $0.1086 to $0.1184, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of ADSs sold at each separate price within the ranges set forth in this footnote.
F5: After this transaction, the reporting persons beneficially owned 21,748,780 ADSs, including 20,569,634 ADS held by Qualified Fund representing 123,417,804 Ordinary Shares.
F6: The reporting persons sold 447,910 ADSs representing 2,687,460 Ordinary Shares. Qualified Fund sold 418,303 of those ADSs, representing 2,509,818 Ordinary Shares.
F7: The price reported in Column 4 is the price per ADS sold by the reporting persons.
F8: After this transaction, the reporting persons beneficially owned 21,300,870 ADSs, including 20,151,331 ADSs held by Qualified Fund representing 120,907,986 Ordinary Shares.
F9: The reporting persons sold 4,572,223 ADSs representing 27,433,338 Ordinary Shares. Qualified Fund sold 4,270,000 of those ADSs, representing 25,620,000 Ordinary Shares.
F10: After this transaction, the reporting persons beneficially owned 16,728,647 ADSs, including 15,881,331 ADSs held by Qualified Fund representing 95,287,986 Ordinary Shares.
Akouos, Inc.
Report date June 30, 2020 · Filed July 02, 2020
Section 16 reporting ended · disclosed 2020-07-02. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectSee Notes 2 and 3 | 1,975,984 |
Last balance in matching sequence
After 2020-06-30 transaction · row 2
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
2 source rowsRow 1 · 2020-06-30 · Conversion · Acquired 799,984 · Balance 799,984 F1: The Series B Convertible Preferred Stock converted into Common Stock on a 21.073-for-1 basis without payment of further consideration upon closing of the initial public offering of the Issuer's Common Stock. Qualified acquired 386,974 shares of Common Stock on such conversion, and Venture acquired 321,641 shares of Common Stock on such conversion. The Series B Convertible Preferred Stock had no expiration date. F2: The Filers are EcoR1 Capital, LLC (EcoR1), Oleg Nodelman, EcoR1 Capital Fund Qualified, L.P. (Qualified), EcoR1 Venture Opportunity Fund, L.P. (Venture) and Biotech Opportunity GP, LLC (Biotech). EcoR1 is the investment adviser of private funds, including Qualified and Venture (collectively, the Funds). Biotech is the general partner of Venture, and EcoR1 is the general partner of Qualified. Mr. Nodelman is the manager and controlling owner of EcoR1 and Biotech. EcoR1 is filing this report for itself, Mr. Nodelman, Qualified, Venture and Biotech. The Filers are filing this Form 4 jointly, but not as a group, and each expressly disclaims membership in a group within the meaning of Rule 13d-5(b) under the Securities Exchange Act of 1934, as amended. F3: The Funds hold the securities reported herein directly for the benefit of their investors. Qualified holds 1,383,048 shares of Common Stock, and Venture holds 321,641 shares of Common Stock. EcoR1 indirectly beneficially owns the securities reported herein as the investment adviser to the Funds, and Biotech indirectly beneficially owns the securities held by Venture as the general partner of Venture. Mr. Nodelman indirectly beneficially owns the securities reported herein as the control person of EcoR1 and Biotech. The Filers disclaim beneficial ownership of such securities except to the extent of their pecuniary interest therein. Row 2 · 2020-06-30 · Purchase · Acquired 1,176,000 · Balance 1,975,984 F4: Qualified purchased 996,074 shares of Common Stock in the transaction. F2: The Filers are EcoR1 Capital, LLC (EcoR1), Oleg Nodelman, EcoR1 Capital Fund Qualified, L.P. (Qualified), EcoR1 Venture Opportunity Fund, L.P. (Venture) and Biotech Opportunity GP, LLC (Biotech). EcoR1 is the investment adviser of private funds, including Qualified and Venture (collectively, the Funds). Biotech is the general partner of Venture, and EcoR1 is the general partner of Qualified. Mr. Nodelman is the manager and controlling owner of EcoR1 and Biotech. EcoR1 is filing this report for itself, Mr. Nodelman, Qualified, Venture and Biotech. The Filers are filing this Form 4 jointly, but not as a group, and each expressly disclaims membership in a group within the meaning of Rule 13d-5(b) under the Securities Exchange Act of 1934, as amended. F3: The Funds hold the securities reported herein directly for the benefit of their investors. Qualified holds 1,383,048 shares of Common Stock, and Venture holds 321,641 shares of Common Stock. EcoR1 indirectly beneficially owns the securities reported herein as the investment adviser to the Funds, and Biotech indirectly beneficially owns the securities held by Venture as the general partner of Venture. Mr. Nodelman indirectly beneficially owns the securities reported herein as the control person of EcoR1 and Biotech. The Filers disclaim beneficial ownership of such securities except to the extent of their pecuniary interest therein. |
| Series B Convertible Preferred StockSEC Table II · derivative / convertible security | IndirectSee Notes 2 and 3 | 0 |
Reported balance
After 2020-06-30 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2020-06-30 · Conversion · Disposed 16,858,076 · Balance 0 F1: The Series B Convertible Preferred Stock converted into Common Stock on a 21.073-for-1 basis without payment of further consideration upon closing of the initial public offering of the Issuer's Common Stock. Qualified acquired 386,974 shares of Common Stock on such conversion, and Venture acquired 321,641 shares of Common Stock on such conversion. The Series B Convertible Preferred Stock had no expiration date. F2: The Filers are EcoR1 Capital, LLC (EcoR1), Oleg Nodelman, EcoR1 Capital Fund Qualified, L.P. (Qualified), EcoR1 Venture Opportunity Fund, L.P. (Venture) and Biotech Opportunity GP, LLC (Biotech). EcoR1 is the investment adviser of private funds, including Qualified and Venture (collectively, the Funds). Biotech is the general partner of Venture, and EcoR1 is the general partner of Qualified. Mr. Nodelman is the manager and controlling owner of EcoR1 and Biotech. EcoR1 is filing this report for itself, Mr. Nodelman, Qualified, Venture and Biotech. The Filers are filing this Form 4 jointly, but not as a group, and each expressly disclaims membership in a group within the meaning of Rule 13d-5(b) under the Securities Exchange Act of 1934, as amended. F3: The Funds hold the securities reported herein directly for the benefit of their investors. Qualified holds 1,383,048 shares of Common Stock, and Venture holds 321,641 shares of Common Stock. EcoR1 indirectly beneficially owns the securities reported herein as the investment adviser to the Funds, and Biotech indirectly beneficially owns the securities held by Venture as the general partner of Venture. Mr. Nodelman indirectly beneficially owns the securities reported herein as the control person of EcoR1 and Biotech. The Filers disclaim beneficial ownership of such securities except to the extent of their pecuniary interest therein. |
Filing footnotes · ownership attribution and instrument terms
F1: The Series B Convertible Preferred Stock converted into Common Stock on a 21.073-for-1 basis without payment of further consideration upon closing of the initial public offering of the Issuer's Common Stock. Qualified acquired 386,974 shares of Common Stock on such conversion, and Venture acquired 321,641 shares of Common Stock on such conversion. The Series B Convertible Preferred Stock had no expiration date.
F2: The Filers are EcoR1 Capital, LLC (EcoR1), Oleg Nodelman, EcoR1 Capital Fund Qualified, L.P. (Qualified), EcoR1 Venture Opportunity Fund, L.P. (Venture) and Biotech Opportunity GP, LLC (Biotech). EcoR1 is the investment adviser of private funds, including Qualified and Venture (collectively, the Funds). Biotech is the general partner of Venture, and EcoR1 is the general partner of Qualified. Mr. Nodelman is the manager and controlling owner of EcoR1 and Biotech. EcoR1 is filing this report for itself, Mr. Nodelman, Qualified, Venture and Biotech. The Filers are filing this Form 4 jointly, but not as a group, and each expressly disclaims membership in a group within the meaning of Rule 13d-5(b) under the Securities Exchange Act of 1934, as amended.
F3: The Funds hold the securities reported herein directly for the benefit of their investors. Qualified holds 1,383,048 shares of Common Stock, and Venture holds 321,641 shares of Common Stock. EcoR1 indirectly beneficially owns the securities reported herein as the investment adviser to the Funds, and Biotech indirectly beneficially owns the securities held by Venture as the general partner of Venture. Mr. Nodelman indirectly beneficially owns the securities reported herein as the control person of EcoR1 and Biotech. The Filers disclaim beneficial ownership of such securities except to the extent of their pecuniary interest therein.
F4: Qualified purchased 996,074 shares of Common Stock in the transaction.
Corvus Pharmaceuticals, Inc.
Report date September 30, 2021 · Filed October 01, 2021
Section 16 reporting ended · disclosed 2021-10-01. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectSee Note 2 | 2,081,077 |
Reported balance
After 2021-09-30 transaction · row 1
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 1 · 2021-09-30 · Sale · Disposed 3,000,000 · Balance 2,081,077 F1: EcoR1 Capital Fund Qualified, L.P. ("Qualified Fund") sold 2,643,300 shares of Common Stock in this transaction and held 1,803,513 shares of Common Stock following this transaction. F2: The filing persons (the "Filers") are EcoR1 Capital, LLC ("EcoR1"), Oleg Nodelman and Qualified Fund. EcoR1 is the general partner and investment adviser of private funds, including Qualified Fund (collectively, the "Funds"). Mr. Nodelman is the manager and controlling owner of EcoR1. EcoR1 is filing this Form 4 for itself, Mr. Nodelman and Qualified Fund. The Filers are filing this Form 4 jointly, but not as a group, and each expressly disclaims membership in a group, within the meaning of Rule 13d-5(b) under the Securities Exchange Act of 1934, as amended. The Funds hold these securities directly for the benefit of their investors. EcoR1 indirectly beneficially owns them as the investment adviser to the Funds, and Mr. Nodelman indirectly beneficially owns them as the control person of EcoR1. The Filers disclaim beneficial ownership of such securities except to the extent of their respective pecuniary interests therein. |
| Common StockSEC Table I · non-derivative | IndirectSee Note 2 | 81,077 |
Reported balance
After 2021-10-01 transaction · row 2
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 2 · 2021-10-01 · Sale · Disposed 2,000,000 · Balance 81,077 F3: Qualified Fund sold 1,760,600 shares of Common Stock in this transaction and held 42,913 shares of Common Stock following this transaction. F2: The filing persons (the "Filers") are EcoR1 Capital, LLC ("EcoR1"), Oleg Nodelman and Qualified Fund. EcoR1 is the general partner and investment adviser of private funds, including Qualified Fund (collectively, the "Funds"). Mr. Nodelman is the manager and controlling owner of EcoR1. EcoR1 is filing this Form 4 for itself, Mr. Nodelman and Qualified Fund. The Filers are filing this Form 4 jointly, but not as a group, and each expressly disclaims membership in a group, within the meaning of Rule 13d-5(b) under the Securities Exchange Act of 1934, as amended. The Funds hold these securities directly for the benefit of their investors. EcoR1 indirectly beneficially owns them as the investment adviser to the Funds, and Mr. Nodelman indirectly beneficially owns them as the control person of EcoR1. The Filers disclaim beneficial ownership of such securities except to the extent of their respective pecuniary interests therein. |
Filing footnotes · ownership attribution and instrument terms
F1: EcoR1 Capital Fund Qualified, L.P. ("Qualified Fund") sold 2,643,300 shares of Common Stock in this transaction and held 1,803,513 shares of Common Stock following this transaction.
F2: The filing persons (the "Filers") are EcoR1 Capital, LLC ("EcoR1"), Oleg Nodelman and Qualified Fund. EcoR1 is the general partner and investment adviser of private funds, including Qualified Fund (collectively, the "Funds"). Mr. Nodelman is the manager and controlling owner of EcoR1. EcoR1 is filing this Form 4 for itself, Mr. Nodelman and Qualified Fund. The Filers are filing this Form 4 jointly, but not as a group, and each expressly disclaims membership in a group, within the meaning of Rule 13d-5(b) under the Securities Exchange Act of 1934, as amended. The Funds hold these securities directly for the benefit of their investors. EcoR1 indirectly beneficially owns them as the investment adviser to the Funds, and Mr. Nodelman indirectly beneficially owns them as the control person of EcoR1. The Filers disclaim beneficial ownership of such securities except to the extent of their respective pecuniary interests therein.
F3: Qualified Fund sold 1,760,600 shares of Common Stock in this transaction and held 42,913 shares of Common Stock following this transaction.
First Tracks Biotherapeutics, Inc.
Report date April 20, 2026 · Filed April 22, 2026
Section 16 reporting ended · disclosed 2026-04-22. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectSee Note | 3,174,519 |
Reported balance
After 2026-04-20 transaction · row 1
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 1 · 2026-04-20 · Sale · Acquired 4,705,575 · Balance 3,174,519 F2: The Funds sold these share in a private placement described in the Form 8K filed by the Issuer on April 20, 2026. F3: Qualified Fund sold 4,420,064 of the securities in this transaction. F4: After this transaction, Qualified Fund holds 2,981,908 shares of the Issuer's Common Stock. F1: The reporting persons are EcoR1 Capital, LLC ("EcoR1"), Oleg Nodelman and EcoR1 Capital Fund Qualified L.P. ("Qualified Fund"). EcoR1 is the investment adviser and general partner of private funds, including Qualified Fund (collectively, the "Funds"). Mr. Nodelman is the manager and controlling owner of EcoR1. EcoR1 is filing this Form 4 for itself, Mr. Nodelman and Qualified Fund. The filers are filing this Form 4 jointly, but not as a group, and each expressly disclaims membership in a group within the meaning of Rule 13d-5(b) under the Securities Exchange Act of 1934. The Funds hold these securities directly for the benefit of their investors. EcoR1 may be deemed to indirectly beneficially own them as the investment adviser to the Funds. Mr. Nodelman may be deemed to indirectly beneficially own them as the control person of EcoR1. The filers disclaim beneficial ownership of such securities except to the extent of their pecuniary interests therein. |
Filing footnotes · ownership attribution and instrument terms
F1: The reporting persons are EcoR1 Capital, LLC ("EcoR1"), Oleg Nodelman and EcoR1 Capital Fund Qualified L.P. ("Qualified Fund"). EcoR1 is the investment adviser and general partner of private funds, including Qualified Fund (collectively, the "Funds"). Mr. Nodelman is the manager and controlling owner of EcoR1. EcoR1 is filing this Form 4 for itself, Mr. Nodelman and Qualified Fund. The filers are filing this Form 4 jointly, but not as a group, and each expressly disclaims membership in a group within the meaning of Rule 13d-5(b) under the Securities Exchange Act of 1934. The Funds hold these securities directly for the benefit of their investors. EcoR1 may be deemed to indirectly beneficially own them as the investment adviser to the Funds. Mr. Nodelman may be deemed to indirectly beneficially own them as the control person of EcoR1. The filers disclaim beneficial ownership of such securities except to the extent of their pecuniary interests therein.
F2: The Funds sold these share in a private placement described in the Form 8K filed by the Issuer on April 20, 2026.
F3: Qualified Fund sold 4,420,064 of the securities in this transaction.
F4: After this transaction, Qualified Fund holds 2,981,908 shares of the Issuer's Common Stock.
Mersana Therapeutics, Inc.
Report date December 19, 2024 · Filed December 24, 2024
Section 16 reporting ended · disclosed 2024-12-24. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectSee Note | 11,328,000 |
Reported balance
After 2024-12-19 transaction · row 1
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 1 · 2024-12-19 · Other · Disposed 8,036,688 · Balance 11,328,000 F2: The Funds exchanged 8,036,688 shares of Common Stock for pre-funded warrants to acquire 8,036,688 shares of Common Stock F3: Qualified Fund disposed of 7,578,596 shares of Common Stock disposed of in this exchange F4: After this transaction, Qualified Fund owns 10,682,303 shares of Common Stock. F1: The reporting persons are EcoR1 Capital, LLC ("EcoR1"), Oleg Nodelman and EcoR1 Capital Fund Qualified, L.P. ("Qualified Fund"). EcoR1 is the general partner and investment adviser of private funds, including Qualified Fund (the "Funds"). Mr. Nodelman is the manager and controlling owner of EcoR1. EcoR1 is filing this Form 4 for itself, Mr. Nodelman and Qualified Fund. The filers are filing this Form 4 jointly, but not as a group, and each expressly disclaims membership in a group within the meaning of Rule 13d-5(b) under the Securities Exchange Act of 1934. The Funds hold these securities directly for the benefit of their investors. EcoR1 may be deemed to indirectly beneficially own them as the investment adviser to the Funds. Mr. Nodelman may be deemed to indirectly beneficially own them as the control person of EcoR1. The filers disclaim beneficial ownership of the securities except to the extent of their respective pecuniary interests therein. |
| Pre-Funded WarrantsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | IndirectSee Note | 8,036,688 |
Reported balance
After 2024-12-19 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2024-12-19 · Other · Acquired 8,036,688 · Balance 8,036,688 F2: The Funds exchanged 8,036,688 shares of Common Stock for pre-funded warrants to acquire 8,036,688 shares of Common Stock F5: Qualified Fund acquired 7,578,596 of the pre-funded warrants acquired in this exchange. F6: The pre-funded warrants do not have an expiration date. F7: Each pre-funded warrant is exercisable to purchase one share of Common Stock, except that a holder of a pre-funded warrant will not be entitled to exercise any pre-funded warrant if, upon giving effect or immediately prior to such exercise, such exercise would result in (i) the aggregate number of shares of Common Stock beneficially owned by such holder (together with its affiliates) exceeding 9.99% of the number of shares of Common Stock outstanding immediately after giving effect to such exercise, or (ii) the combined voting power of Company securities beneficially owned by such holder (together with its affiliates) exceeding 9.99% of the combined voting power of all Company securities outstanding immediately after giving effect to such exercise, as such percentage ownership is determined in accordance with the terms of the pre-funded warrants. F8: After this transaction, Qualified Fund owned 7,578,596 of the pre-funded warrants. F1: The reporting persons are EcoR1 Capital, LLC ("EcoR1"), Oleg Nodelman and EcoR1 Capital Fund Qualified, L.P. ("Qualified Fund"). EcoR1 is the general partner and investment adviser of private funds, including Qualified Fund (the "Funds"). Mr. Nodelman is the manager and controlling owner of EcoR1. EcoR1 is filing this Form 4 for itself, Mr. Nodelman and Qualified Fund. The filers are filing this Form 4 jointly, but not as a group, and each expressly disclaims membership in a group within the meaning of Rule 13d-5(b) under the Securities Exchange Act of 1934. The Funds hold these securities directly for the benefit of their investors. EcoR1 may be deemed to indirectly beneficially own them as the investment adviser to the Funds. Mr. Nodelman may be deemed to indirectly beneficially own them as the control person of EcoR1. The filers disclaim beneficial ownership of the securities except to the extent of their respective pecuniary interests therein. |
Filing footnotes · ownership attribution and instrument terms
F1: The reporting persons are EcoR1 Capital, LLC ("EcoR1"), Oleg Nodelman and EcoR1 Capital Fund Qualified, L.P. ("Qualified Fund"). EcoR1 is the general partner and investment adviser of private funds, including Qualified Fund (the "Funds"). Mr. Nodelman is the manager and controlling owner of EcoR1. EcoR1 is filing this Form 4 for itself, Mr. Nodelman and Qualified Fund. The filers are filing this Form 4 jointly, but not as a group, and each expressly disclaims membership in a group within the meaning of Rule 13d-5(b) under the Securities Exchange Act of 1934. The Funds hold these securities directly for the benefit of their investors. EcoR1 may be deemed to indirectly beneficially own them as the investment adviser to the Funds. Mr. Nodelman may be deemed to indirectly beneficially own them as the control person of EcoR1. The filers disclaim beneficial ownership of the securities except to the extent of their respective pecuniary interests therein.
F2: The Funds exchanged 8,036,688 shares of Common Stock for pre-funded warrants to acquire 8,036,688 shares of Common Stock
F3: Qualified Fund disposed of 7,578,596 shares of Common Stock disposed of in this exchange
F4: After this transaction, Qualified Fund owns 10,682,303 shares of Common Stock.
F5: Qualified Fund acquired 7,578,596 of the pre-funded warrants acquired in this exchange.
F6: The pre-funded warrants do not have an expiration date.
F7: Each pre-funded warrant is exercisable to purchase one share of Common Stock, except that a holder of a pre-funded warrant will not be entitled to exercise any pre-funded warrant if, upon giving effect or immediately prior to such exercise, such exercise would result in (i) the aggregate number of shares of Common Stock beneficially owned by such holder (together with its affiliates) exceeding 9.99% of the number of shares of Common Stock outstanding immediately after giving effect to such exercise, or (ii) the combined voting power of Company securities beneficially owned by such holder (together with its affiliates) exceeding 9.99% of the combined voting power of all Company securities outstanding immediately after giving effect to such exercise, as such percentage ownership is determined in accordance with the terms of the pre-funded warrants.
F8: After this transaction, Qualified Fund owned 7,578,596 of the pre-funded warrants.
Odonate Therapeutics, Inc.
Report date December 01, 2021 · Filed December 10, 2021
Section 16 reporting ended · disclosed 2021-12-10. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectSee Note 1 | 5,701,669 |
Reported balance
After 2021-12-01 transaction · row 1
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 1 · 2021-12-01 · Purchase · Acquired 185,941 · Balance 5,701,669 F2: These securities were transferred from another Fund managed by EcoR1 to Qualified Fund as part of a periodic rebalancing of the portfolios of the Funds. After this transaction, Qualified Fund held 5,185,698 shares of the Issuer's Common Stock, and the other fund held 515,971 shares. F1: The filing persons (the "Filers") are EcoR1 Capital, LLC ("EcoR1"), Oleg Nodelman and EcoR1 Capital Fund Qualified, L.P. ("Qualified Fund"). EcoR1 is the general partner and investment adviser of private funds, including Qualified Fund (collectively, the "Funds"). Mr. Nodelman is the manager and controlling owner of EcoR1. EcoR1 is filing this Form 4 for itself, Mr. Nodelman and Qualified Fund. The Filers are filing this Form 4 jointly, but not as a group, and each expressly disclaims membership in a group, within the meaning of Rule 13d-5(b) under the Securities Exchange Act of 1934, as amended. The Funds held these securities directly for the benefit of their investors. EcoR1 indirectly beneficially owned them as the investment adviser to the Funds, and Mr. Nodelman indirectly beneficially owned them as the control person of EcoR1. The Filers disclaim beneficial ownership of such securities except to the extent of their respective pecuniary interests therein. |
| Common StockSEC Table I · non-derivative | IndirectSee Note 1 | 5,701,669 |
Reported balance
After 2021-12-01 transaction · row 2
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 2 · 2021-12-01 · Sale · Disposed 185,941 · Balance 5,701,669 F2: These securities were transferred from another Fund managed by EcoR1 to Qualified Fund as part of a periodic rebalancing of the portfolios of the Funds. After this transaction, Qualified Fund held 5,185,698 shares of the Issuer's Common Stock, and the other fund held 515,971 shares. F1: The filing persons (the "Filers") are EcoR1 Capital, LLC ("EcoR1"), Oleg Nodelman and EcoR1 Capital Fund Qualified, L.P. ("Qualified Fund"). EcoR1 is the general partner and investment adviser of private funds, including Qualified Fund (collectively, the "Funds"). Mr. Nodelman is the manager and controlling owner of EcoR1. EcoR1 is filing this Form 4 for itself, Mr. Nodelman and Qualified Fund. The Filers are filing this Form 4 jointly, but not as a group, and each expressly disclaims membership in a group, within the meaning of Rule 13d-5(b) under the Securities Exchange Act of 1934, as amended. The Funds held these securities directly for the benefit of their investors. EcoR1 indirectly beneficially owned them as the investment adviser to the Funds, and Mr. Nodelman indirectly beneficially owned them as the control person of EcoR1. The Filers disclaim beneficial ownership of such securities except to the extent of their respective pecuniary interests therein. |
| Common StockSEC Table I · non-derivative | IndirectSee Note 1 | 5,545,000 |
Reported balance
After 2021-12-09 transaction · row 3
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 3 · 2021-12-09 · Sale · Disposed 156,669 · Balance 5,545,000 F3: Qualified Fund sold 142,491 of these shares. After this transaction, Qualified Fund held 5,043,207 shares of the Issuer's Common Stock. F1: The filing persons (the "Filers") are EcoR1 Capital, LLC ("EcoR1"), Oleg Nodelman and EcoR1 Capital Fund Qualified, L.P. ("Qualified Fund"). EcoR1 is the general partner and investment adviser of private funds, including Qualified Fund (collectively, the "Funds"). Mr. Nodelman is the manager and controlling owner of EcoR1. EcoR1 is filing this Form 4 for itself, Mr. Nodelman and Qualified Fund. The Filers are filing this Form 4 jointly, but not as a group, and each expressly disclaims membership in a group, within the meaning of Rule 13d-5(b) under the Securities Exchange Act of 1934, as amended. The Funds held these securities directly for the benefit of their investors. EcoR1 indirectly beneficially owned them as the investment adviser to the Funds, and Mr. Nodelman indirectly beneficially owned them as the control person of EcoR1. The Filers disclaim beneficial ownership of such securities except to the extent of their respective pecuniary interests therein. |
| Common StockSEC Table I · non-derivative | IndirectSee Note 1 | 545,000 |
Reported balance
After 2021-12-10 transaction · row 4
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 4 · 2021-12-10 · Sale · Disposed 5,000,000 · Balance 545,000 F4: Qualified Fund sold 4,547,500 of these shares. After this transaction, Qualified Fund held 495,707 shares of the Issuer's Common Stock. F1: The filing persons (the "Filers") are EcoR1 Capital, LLC ("EcoR1"), Oleg Nodelman and EcoR1 Capital Fund Qualified, L.P. ("Qualified Fund"). EcoR1 is the general partner and investment adviser of private funds, including Qualified Fund (collectively, the "Funds"). Mr. Nodelman is the manager and controlling owner of EcoR1. EcoR1 is filing this Form 4 for itself, Mr. Nodelman and Qualified Fund. The Filers are filing this Form 4 jointly, but not as a group, and each expressly disclaims membership in a group, within the meaning of Rule 13d-5(b) under the Securities Exchange Act of 1934, as amended. The Funds held these securities directly for the benefit of their investors. EcoR1 indirectly beneficially owned them as the investment adviser to the Funds, and Mr. Nodelman indirectly beneficially owned them as the control person of EcoR1. The Filers disclaim beneficial ownership of such securities except to the extent of their respective pecuniary interests therein. |
| Common StockSEC Table I · non-derivative | IndirectSee Note 1 | 0 |
Reported balance
After 2021-12-10 transaction · row 5
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 5 · 2021-12-10 · Sale · Disposed 545,000 · Balance 0 F5: Qualified Fund sold 495,707 of these shares. After this transaction, Qualified Fund held no shares of the Issuer's Common Stock. F1: The filing persons (the "Filers") are EcoR1 Capital, LLC ("EcoR1"), Oleg Nodelman and EcoR1 Capital Fund Qualified, L.P. ("Qualified Fund"). EcoR1 is the general partner and investment adviser of private funds, including Qualified Fund (collectively, the "Funds"). Mr. Nodelman is the manager and controlling owner of EcoR1. EcoR1 is filing this Form 4 for itself, Mr. Nodelman and Qualified Fund. The Filers are filing this Form 4 jointly, but not as a group, and each expressly disclaims membership in a group, within the meaning of Rule 13d-5(b) under the Securities Exchange Act of 1934, as amended. The Funds held these securities directly for the benefit of their investors. EcoR1 indirectly beneficially owned them as the investment adviser to the Funds, and Mr. Nodelman indirectly beneficially owned them as the control person of EcoR1. The Filers disclaim beneficial ownership of such securities except to the extent of their respective pecuniary interests therein. |
Filing footnotes · ownership attribution and instrument terms
F1: The filing persons (the "Filers") are EcoR1 Capital, LLC ("EcoR1"), Oleg Nodelman and EcoR1 Capital Fund Qualified, L.P. ("Qualified Fund"). EcoR1 is the general partner and investment adviser of private funds, including Qualified Fund (collectively, the "Funds"). Mr. Nodelman is the manager and controlling owner of EcoR1. EcoR1 is filing this Form 4 for itself, Mr. Nodelman and Qualified Fund. The Filers are filing this Form 4 jointly, but not as a group, and each expressly disclaims membership in a group, within the meaning of Rule 13d-5(b) under the Securities Exchange Act of 1934, as amended. The Funds held these securities directly for the benefit of their investors. EcoR1 indirectly beneficially owned them as the investment adviser to the Funds, and Mr. Nodelman indirectly beneficially owned them as the control person of EcoR1. The Filers disclaim beneficial ownership of such securities except to the extent of their respective pecuniary interests therein.
F2: These securities were transferred from another Fund managed by EcoR1 to Qualified Fund as part of a periodic rebalancing of the portfolios of the Funds. After this transaction, Qualified Fund held 5,185,698 shares of the Issuer's Common Stock, and the other fund held 515,971 shares.
F3: Qualified Fund sold 142,491 of these shares. After this transaction, Qualified Fund held 5,043,207 shares of the Issuer's Common Stock.
F4: Qualified Fund sold 4,547,500 of these shares. After this transaction, Qualified Fund held 495,707 shares of the Issuer's Common Stock.
F5: Qualified Fund sold 495,707 of these shares. After this transaction, Qualified Fund held no shares of the Issuer's Common Stock.
PROTHENA CORP PUBLIC LTD CO
Report date May 02, 2025 · Filed May 06, 2025
Section 16 reporting ended · disclosed 2025-05-06. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | IndirectSee Note | 8,266,342 |
Reported balance
After 2025-05-02 transaction · row 1
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 1 · 2025-05-02 · Sale · Disposed 3,317,938 · Balance 8,266,342 F2: Qualified Fund sold 3,097,619 of the shares sold in this transaction. F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.2715 to $9.1789, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each seperate price within the ranges set forth in this footnote and footnotes 6 and 9. F4: After this transaction, Qualified Fund held 7,750,234 shares of the Issuer's Common Stock. F1: The reporting persons are EcoR1 Capital, LLC ("Ecor1"), Oleg Nodelman and EcoR1 Capital Fund Qualified, L.P. ("Qualified Fund"). EcoR1 is the general partner and investment adviser of private funds, including Qualified Fund (the "Fund"). Mr. Nodelman is the manager and controlling owner of EcoR1. EcoR1 is filing this Form 4 for itself, Mr. Nodelman and Qualified Fund. The filers are filing this Form 4 jointly, but not as a group, and each expressly disclaims membership in a group within the meaning of Rule 13d-5(b) under the Securities Exchange Act of 1934. The Funds hold these securities directly for the benefit of their investors. EcoR1 may be deemed to indirectly beneficially own them as the investment adviser to the Funds. Mr. Nodelman may be deemed to indirectly beneficially own them as the control person of EcoR1. The filers disclaim beneficial ownership of the securities except to the extent of their respective pecuniary interests therein. |
| Ordinary SharesSEC Table I · non-derivative | IndirectSee Note | 7,288,649 |
Reported balance
After 2025-05-05 transaction · row 2
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 2 · 2025-05-05 · Sale · Disposed 977,693 · Balance 7,288,649 F5: Qualified Fund sold 916,492 of the shares of sold in this transaction. F6: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.1097 to $8.1972, inclusive. F7: After this transaction, Qualified Fund held 6,833,742 shares of the Issuer's Common Stock F1: The reporting persons are EcoR1 Capital, LLC ("Ecor1"), Oleg Nodelman and EcoR1 Capital Fund Qualified, L.P. ("Qualified Fund"). EcoR1 is the general partner and investment adviser of private funds, including Qualified Fund (the "Fund"). Mr. Nodelman is the manager and controlling owner of EcoR1. EcoR1 is filing this Form 4 for itself, Mr. Nodelman and Qualified Fund. The filers are filing this Form 4 jointly, but not as a group, and each expressly disclaims membership in a group within the meaning of Rule 13d-5(b) under the Securities Exchange Act of 1934. The Funds hold these securities directly for the benefit of their investors. EcoR1 may be deemed to indirectly beneficially own them as the investment adviser to the Funds. Mr. Nodelman may be deemed to indirectly beneficially own them as the control person of EcoR1. The filers disclaim beneficial ownership of the securities except to the extent of their respective pecuniary interests therein. |
| Ordinary SharesSEC Table I · non-derivative | IndirectSee Note | 5,304,596 |
Reported balance
After 2025-05-06 transaction · row 3
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 3 · 2025-05-06 · Sale · Disposed 1,984,053 · Balance 5,304,596 F8: Qualified Fund sold 1,859,851 of the shares sold in this transaction. F9: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.4637 to $8.5939, inclusive. F10: After this transaction, Qualified Fund held 4,973,891 of the Issuer's Ordinary Shares. F1: The reporting persons are EcoR1 Capital, LLC ("Ecor1"), Oleg Nodelman and EcoR1 Capital Fund Qualified, L.P. ("Qualified Fund"). EcoR1 is the general partner and investment adviser of private funds, including Qualified Fund (the "Fund"). Mr. Nodelman is the manager and controlling owner of EcoR1. EcoR1 is filing this Form 4 for itself, Mr. Nodelman and Qualified Fund. The filers are filing this Form 4 jointly, but not as a group, and each expressly disclaims membership in a group within the meaning of Rule 13d-5(b) under the Securities Exchange Act of 1934. The Funds hold these securities directly for the benefit of their investors. EcoR1 may be deemed to indirectly beneficially own them as the investment adviser to the Funds. Mr. Nodelman may be deemed to indirectly beneficially own them as the control person of EcoR1. The filers disclaim beneficial ownership of the securities except to the extent of their respective pecuniary interests therein. |
Filing footnotes · ownership attribution and instrument terms
F1: The reporting persons are EcoR1 Capital, LLC ("Ecor1"), Oleg Nodelman and EcoR1 Capital Fund Qualified, L.P. ("Qualified Fund"). EcoR1 is the general partner and investment adviser of private funds, including Qualified Fund (the "Fund"). Mr. Nodelman is the manager and controlling owner of EcoR1. EcoR1 is filing this Form 4 for itself, Mr. Nodelman and Qualified Fund. The filers are filing this Form 4 jointly, but not as a group, and each expressly disclaims membership in a group within the meaning of Rule 13d-5(b) under the Securities Exchange Act of 1934. The Funds hold these securities directly for the benefit of their investors. EcoR1 may be deemed to indirectly beneficially own them as the investment adviser to the Funds. Mr. Nodelman may be deemed to indirectly beneficially own them as the control person of EcoR1. The filers disclaim beneficial ownership of the securities except to the extent of their respective pecuniary interests therein.
F2: Qualified Fund sold 3,097,619 of the shares sold in this transaction.
F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.2715 to $9.1789, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each seperate price within the ranges set forth in this footnote and footnotes 6 and 9.
F4: After this transaction, Qualified Fund held 7,750,234 shares of the Issuer's Common Stock.
F5: Qualified Fund sold 916,492 of the shares of sold in this transaction.
F6: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.1097 to $8.1972, inclusive.
F7: After this transaction, Qualified Fund held 6,833,742 shares of the Issuer's Common Stock
F8: Qualified Fund sold 1,859,851 of the shares sold in this transaction.
F9: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.4637 to $8.5939, inclusive.
F10: After this transaction, Qualified Fund held 4,973,891 of the Issuer's Ordinary Shares.
Panacea Acquisition Corp. II
Report date April 28, 2023 · Filed May 02, 2023
Jointly reported with EcoR1 Panacea Holdings II, LLC, EcoR1 Capital Fund, L.P., EcoR1 Capital Fund Qualified, L.P., EcoR1 Venture Opportunity Fund, LP, Biotech Opportunity GP, LLC, NODELMAN OLEG
Section 16 reporting ended · disclosed 2023-05-02. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A ordinary sharesSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2023-04-28 transaction · row 1
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 1 · 2023-04-28 · Disposition to issuer · Disposed 545,000 · Balance 0 F1: On April 10, 2023, Panacea Acquisition Corp. II (the "Company") announced that it did not consummate an initial business combination by April 9, 2023, the deadline under its Amended and Restated Memorandum and Articles of Association. In connection with the winding up of the Company, the Class A ordinary shares, par value $0.0001 per share, held by the Reporting Persons were surrendered for no consideration on April 28, 2023. F2: The reporting owner, EcoR1 Panacea Holdings II, LLC (the "Sponsor"), in whose name the securities reported herein were held, is managed by its managing members, EcoR1 Capital Fund, L.P., EcoR1 Capital Fund Qualified, L.P. and EcoR1 Venture Opportunity Fund, L.P. The general partner of EcoR1 Capital Fund, L.P. and EcoR1 Capital Fund Qualified, L.P. is EcoR1 Capital, LLC and the general partner of EcoR1 Venture Opportunity Fund, L.P. is Biotech Opportunity GP, LLC (together with EcoR1 Capital, LLC, the "General Partners"). Oleg Nodelman is the manager of each of the General Partners. Each of the Reporting Persons may have been deemed to be a beneficial owner of the shares held by the Sponsor but each (other than the Sponsor) disclaims beneficial ownership of any such shares except to the extent of its respective pecuniary interest therein. |
Filing footnotes · ownership attribution and instrument terms
F1: On April 10, 2023, Panacea Acquisition Corp. II (the "Company") announced that it did not consummate an initial business combination by April 9, 2023, the deadline under its Amended and Restated Memorandum and Articles of Association. In connection with the winding up of the Company, the Class A ordinary shares, par value $0.0001 per share, held by the Reporting Persons were surrendered for no consideration on April 28, 2023.
F2: The reporting owner, EcoR1 Panacea Holdings II, LLC (the "Sponsor"), in whose name the securities reported herein were held, is managed by its managing members, EcoR1 Capital Fund, L.P., EcoR1 Capital Fund Qualified, L.P. and EcoR1 Venture Opportunity Fund, L.P. The general partner of EcoR1 Capital Fund, L.P. and EcoR1 Capital Fund Qualified, L.P. is EcoR1 Capital, LLC and the general partner of EcoR1 Venture Opportunity Fund, L.P. is Biotech Opportunity GP, LLC (together with EcoR1 Capital, LLC, the "General Partners"). Oleg Nodelman is the manager of each of the General Partners. Each of the Reporting Persons may have been deemed to be a beneficial owner of the shares held by the Sponsor but each (other than the Sponsor) disclaims beneficial ownership of any such shares except to the extent of its respective pecuniary interest therein.
Surface Oncology, Inc.
Report date September 01, 2020 · Filed September 03, 2020
Section 16 reporting ended · disclosed 2020-09-03. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectSee note 1 | 4,701,081 |
Reported balance
After 2020-09-01 transaction · row 1
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 1 · 2020-09-01 · Sale · Disposed 332,780 · Balance 4,701,081 F1: The Filers are EcoR1 Capital, LLC (EcoR1), Oleg Nodelman and EcoR1 Capital Fund Qualified, L.P. (Qualified). EcoR1 is the general partner and investment adviser of private funds, including Qualified (collectively, the Funds). Mr. Nodelman is the manager and controlling owner of EcoR1. EcoR1 is filing this report for itself, Mr. Nodelman and Qualified. The Filers are filing this Form 4 jointly, but not as a group, and each expressly disclaims membership in a group within the meaning of Rule 13d-5(b) under the Securities Exchange Act of 1934. The Funds hold these securities directly for the benefit of their investors. EcoR1 indirectly beneficially owns the securities reported herein as the investment adviser to the Funds, and Mr. Nodelman indirectly beneficially owns them as the control person of EcoR1. The Filers disclaim beneficial ownership of the securities except to the extent of their pecuniary interest therein. F2: Qualified sold 281,132 shares of the securities sold in the transaction and holds 3,981,674 shares of such securities after the transaction. |
Filing footnotes · ownership attribution and instrument terms
F1: The Filers are EcoR1 Capital, LLC (EcoR1), Oleg Nodelman and EcoR1 Capital Fund Qualified, L.P. (Qualified). EcoR1 is the general partner and investment adviser of private funds, including Qualified (collectively, the Funds). Mr. Nodelman is the manager and controlling owner of EcoR1. EcoR1 is filing this report for itself, Mr. Nodelman and Qualified. The Filers are filing this Form 4 jointly, but not as a group, and each expressly disclaims membership in a group within the meaning of Rule 13d-5(b) under the Securities Exchange Act of 1934. The Funds hold these securities directly for the benefit of their investors. EcoR1 indirectly beneficially owns the securities reported herein as the investment adviser to the Funds, and Mr. Nodelman indirectly beneficially owns them as the control person of EcoR1. The Filers disclaim beneficial ownership of the securities except to the extent of their pecuniary interest therein.
F2: Qualified sold 281,132 shares of the securities sold in the transaction and holds 3,981,674 shares of such securities after the transaction.
Tango Therapeutics, Inc.
Report date November 06, 2024 · Filed November 09, 2024
Section 16 reporting ended · disclosed 2024-11-09. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectSee Note | 11,836,178 |
Reported balance
After 2024-11-06 transaction · row 1
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 1 · 2024-11-06 · Sale · Disposed 1,494,558 · Balance 11,836,178 F2: Qualified Fund sold 1,406,529 of the shares sold in this transaction. F3: After this transaction, Qualified Fund held 11,156,852 shares of Issuer's Common Stock. F1: The filers are EcoR1 Capital, LLC ("EcoR1"), Oleg Nodelman and EcoR1 Capital Fund Qualified, L.P. ("Qualified Fund"). EcoR1 is the investment adviser and general partner of private funds, including Qualified Fund (collectively, the "Funds"). Mr. Nodelman is the manager and controlling owner of EcoR1. EcoR1 is filing this Form 4 for itself, Qualified Fund and Mr. Nodelman. The filers are filing this Form 4 jointly, but not as a group, and each expressly disclaims membership in a group within the meaning of Rule 13d-5(b) under the Securities Exchange Act of 1934, as amended. The Funds hold these securities directly for the benefit of their investors. EcoR1 may be deemed to indirectly beneficially own them as the investment adviser to the Funds. Mr. Nodelman may be deemed to indirectly beneficially own them as the control person of EcoR1. The filers disclaim ownership of such securities except to the extent of their respective pecuniary interests therein. |
| Common StockSEC Table I · non-derivative | IndirectSee Note | 11,773,860 |
Reported balance
After 2024-11-07 transaction · row 2
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 2 · 2024-11-07 · Sale · Disposed 62,318 · Balance 11,773,860 F4: Qualified Fund sold 58,647 of the shares sold in this transaction. F5: After this transaction, Qualified Fund held 11,098,205 shares of Issuer's Common Stock. F1: The filers are EcoR1 Capital, LLC ("EcoR1"), Oleg Nodelman and EcoR1 Capital Fund Qualified, L.P. ("Qualified Fund"). EcoR1 is the investment adviser and general partner of private funds, including Qualified Fund (collectively, the "Funds"). Mr. Nodelman is the manager and controlling owner of EcoR1. EcoR1 is filing this Form 4 for itself, Qualified Fund and Mr. Nodelman. The filers are filing this Form 4 jointly, but not as a group, and each expressly disclaims membership in a group within the meaning of Rule 13d-5(b) under the Securities Exchange Act of 1934, as amended. The Funds hold these securities directly for the benefit of their investors. EcoR1 may be deemed to indirectly beneficially own them as the investment adviser to the Funds. Mr. Nodelman may be deemed to indirectly beneficially own them as the control person of EcoR1. The filers disclaim ownership of such securities except to the extent of their respective pecuniary interests therein. |
| Common StockSEC Table I · non-derivative | IndirectSee Note | 10,630,736 |
Reported balance
After 2024-11-07 transaction · row 3
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 3 · 2024-11-07 · Sale · Disposed 1,143,124 · Balance 10,630,736 F6: Qualified Fund sold 1,075,794 of the shares sold in this transaction. F7: After this transaction, Qualified Fund held 10,022,411 shares of Issuer's Common Stock. F1: The filers are EcoR1 Capital, LLC ("EcoR1"), Oleg Nodelman and EcoR1 Capital Fund Qualified, L.P. ("Qualified Fund"). EcoR1 is the investment adviser and general partner of private funds, including Qualified Fund (collectively, the "Funds"). Mr. Nodelman is the manager and controlling owner of EcoR1. EcoR1 is filing this Form 4 for itself, Qualified Fund and Mr. Nodelman. The filers are filing this Form 4 jointly, but not as a group, and each expressly disclaims membership in a group within the meaning of Rule 13d-5(b) under the Securities Exchange Act of 1934, as amended. The Funds hold these securities directly for the benefit of their investors. EcoR1 may be deemed to indirectly beneficially own them as the investment adviser to the Funds. Mr. Nodelman may be deemed to indirectly beneficially own them as the control person of EcoR1. The filers disclaim ownership of such securities except to the extent of their respective pecuniary interests therein. |
Filing footnotes · ownership attribution and instrument terms
F1: The filers are EcoR1 Capital, LLC ("EcoR1"), Oleg Nodelman and EcoR1 Capital Fund Qualified, L.P. ("Qualified Fund"). EcoR1 is the investment adviser and general partner of private funds, including Qualified Fund (collectively, the "Funds"). Mr. Nodelman is the manager and controlling owner of EcoR1. EcoR1 is filing this Form 4 for itself, Qualified Fund and Mr. Nodelman. The filers are filing this Form 4 jointly, but not as a group, and each expressly disclaims membership in a group within the meaning of Rule 13d-5(b) under the Securities Exchange Act of 1934, as amended. The Funds hold these securities directly for the benefit of their investors. EcoR1 may be deemed to indirectly beneficially own them as the investment adviser to the Funds. Mr. Nodelman may be deemed to indirectly beneficially own them as the control person of EcoR1. The filers disclaim ownership of such securities except to the extent of their respective pecuniary interests therein.
F2: Qualified Fund sold 1,406,529 of the shares sold in this transaction.
F3: After this transaction, Qualified Fund held 11,156,852 shares of Issuer's Common Stock.
F4: Qualified Fund sold 58,647 of the shares sold in this transaction.
F5: After this transaction, Qualified Fund held 11,098,205 shares of Issuer's Common Stock.
F6: Qualified Fund sold 1,075,794 of the shares sold in this transaction.
F7: After this transaction, Qualified Fund held 10,022,411 shares of Issuer's Common Stock.
Voyager Therapeutics, Inc.
Report date January 09, 2023 · Filed January 11, 2023
Section 16 reporting ended · disclosed 2023-01-11. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectSee Note 1 | 4,297,907 |
Reported balance
After 2023-01-09 transaction · row 1
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 1 · 2023-01-09 · Sale · Disposed 456,000 · Balance 4,297,907 F2: Qualified Fund sold 429,505 shares of the Common Stock sold in this transaction. F3: After this transaction, Qualified Fund directly owned 3,999,933 shares of Common Stock. F1: The filing persons (the "Filers") are EcoR1 Capital, LLC ("EcoR1"), Oleg Nodelman and EcoR1 Capital Fund Qualified, L.P. ("Qualified Fund"). EcoR1 is the general partner and investment adviser of private funds, including Qualified Fund (collectively, the "Funds"). Mr. Nodelman is the manager and controlling owner of EcoR1. EcoR1 is filing this Form 4 for itself, Mr. Nodelman and Qualified Fund. The Filers are filing this Form 4 jointly, but not as a group, and each expressly disclaims membership in a group, within the meaning of Rule 13d-5(b) under the Securities Exchange Act of 1934, as amended. The Funds hold these securities directly for the benefit of their investors. EcoR1 may be deemed to indirectly beneficially own them as the investment adviser to the Funds, and Mr. Nodelman may be deemed to indirectly beneficially own them as the control person of EcoR1. The Filers disclaim beneficial ownership of such securities except to the extent of their respective pecuniary interests the |
| Common StockSEC Table I · non-derivative | IndirectSee Note 1 | 3,961,507 |
Reported balance
After 2023-01-10 transaction · row 2
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 2 · 2023-01-10 · Sale · Disposed 336,400 · Balance 3,961,507 F4: Qualified Fund sold 268,985 shares of the Common Stock sold in this transaction. F5: After this transaction, Qualified Fund directly owned 3,730,948 shares of Common Stock. F1: The filing persons (the "Filers") are EcoR1 Capital, LLC ("EcoR1"), Oleg Nodelman and EcoR1 Capital Fund Qualified, L.P. ("Qualified Fund"). EcoR1 is the general partner and investment adviser of private funds, including Qualified Fund (collectively, the "Funds"). Mr. Nodelman is the manager and controlling owner of EcoR1. EcoR1 is filing this Form 4 for itself, Mr. Nodelman and Qualified Fund. The Filers are filing this Form 4 jointly, but not as a group, and each expressly disclaims membership in a group, within the meaning of Rule 13d-5(b) under the Securities Exchange Act of 1934, as amended. The Funds hold these securities directly for the benefit of their investors. EcoR1 may be deemed to indirectly beneficially own them as the investment adviser to the Funds, and Mr. Nodelman may be deemed to indirectly beneficially own them as the control person of EcoR1. The Filers disclaim beneficial ownership of such securities except to the extent of their respective pecuniary interests the |
| Common StockSEC Table I · non-derivative | IndirectSee Note 1 | 3,851,507 |
Reported balance
After 2023-01-11 transaction · row 3
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 3 · 2023-01-11 · Sale · Disposed 110,000 · Balance 3,851,507 F6: Qualified Fund sold 103,609 shares of the Common Stock sold in this transaction. F7: After this transaction, Qualified Fund directly owned 3,627,339 shares of Common Stock. F1: The filing persons (the "Filers") are EcoR1 Capital, LLC ("EcoR1"), Oleg Nodelman and EcoR1 Capital Fund Qualified, L.P. ("Qualified Fund"). EcoR1 is the general partner and investment adviser of private funds, including Qualified Fund (collectively, the "Funds"). Mr. Nodelman is the manager and controlling owner of EcoR1. EcoR1 is filing this Form 4 for itself, Mr. Nodelman and Qualified Fund. The Filers are filing this Form 4 jointly, but not as a group, and each expressly disclaims membership in a group, within the meaning of Rule 13d-5(b) under the Securities Exchange Act of 1934, as amended. The Funds hold these securities directly for the benefit of their investors. EcoR1 may be deemed to indirectly beneficially own them as the investment adviser to the Funds, and Mr. Nodelman may be deemed to indirectly beneficially own them as the control person of EcoR1. The Filers disclaim beneficial ownership of such securities except to the extent of their respective pecuniary interests the |
Filing footnotes · ownership attribution and instrument terms
F1: The filing persons (the "Filers") are EcoR1 Capital, LLC ("EcoR1"), Oleg Nodelman and EcoR1 Capital Fund Qualified, L.P. ("Qualified Fund"). EcoR1 is the general partner and investment adviser of private funds, including Qualified Fund (collectively, the "Funds"). Mr. Nodelman is the manager and controlling owner of EcoR1. EcoR1 is filing this Form 4 for itself, Mr. Nodelman and Qualified Fund. The Filers are filing this Form 4 jointly, but not as a group, and each expressly disclaims membership in a group, within the meaning of Rule 13d-5(b) under the Securities Exchange Act of 1934, as amended. The Funds hold these securities directly for the benefit of their investors. EcoR1 may be deemed to indirectly beneficially own them as the investment adviser to the Funds, and Mr. Nodelman may be deemed to indirectly beneficially own them as the control person of EcoR1. The Filers disclaim beneficial ownership of such securities except to the extent of their respective pecuniary interests the
F2: Qualified Fund sold 429,505 shares of the Common Stock sold in this transaction.
F3: After this transaction, Qualified Fund directly owned 3,999,933 shares of Common Stock.
F4: Qualified Fund sold 268,985 shares of the Common Stock sold in this transaction.
F5: After this transaction, Qualified Fund directly owned 3,730,948 shares of Common Stock.
F6: Qualified Fund sold 103,609 shares of the Common Stock sold in this transaction.
F7: After this transaction, Qualified Fund directly owned 3,627,339 shares of Common Stock.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 07, 2026 Filed May 11, 2026 21:34 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | PurchaseCommon Stock | 507,407 | $9.35 | $4,744,255.45 |
DisclosureSEC source: 0000935836-26-000239 · ownership.xml · nonDerivative · entry 1 EcoR1 Capital, LLC · CIK 0001587114 · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · See Note Disclosed balance after: 1,552,000 F2 · shares: Qualified Fund purchased 474,780 of the shares puchased in this transaction. F3 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $8.85 to $9.39 inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote. F4 · balance_after: After this transaction, Qualified Fund held 1,445,609 shares of the Issuer's Common Stock. F1 · ownership.nature: The reporting persons are EcoR1 Capital, LLC ("EcoR1"), Oleg Nodelman and EcoR1 Capital Fund Qualified, L.P. ("Qualified Fund"). EcoR1 is the general partner and investment adviser of private funds, including Qualified Fund (the "Funds"). Mr. Nodelman is the manager and controller owner of EcoR1. EcoR1 is filing this Form 4 for itself, Mr. Nodelman and Qualified Fund. The reporting persons are filing this Form 4 jointly, but not as a group, and each expressly disclaims membership in a group within the meaning of Rule 13d-5(b) under the Securities Exchange Act of 1934. The Funds hold these securities directly for the benefit of their investors. EcoR1 may be deemed to indirectly beneficially own them as the investment adviser to the Funds. Mr. Nodelman may be deemed to indirectly beneficially own them as the control person of EcoR1. The reporting persons disclaim beneficial ownership of the securities except to the extent of their respective pecuniary interests therein. Read SEC document |
| April 20, 2026 Filed Apr 22, 2026 21:07 UTC | First Tracks Biotherapeutics, Inc. TRAX · Entity 4696 | SaleCommon Stock | 4,705,575 | $13.81 | $64,999,989.71 |
DisclosureSEC source: 0000935836-26-000208 · ownership.xml · nonDerivative · entry 1 EcoR1 Capital, LLC · CIK 0001587114 · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · See Note Disclosed balance after: 3,174,519 F2 · kind: The Funds sold these share in a private placement described in the Form 8K filed by the Issuer on April 20, 2026. F3 · shares: Qualified Fund sold 4,420,064 of the securities in this transaction. F4 · balance_after: After this transaction, Qualified Fund holds 2,981,908 shares of the Issuer's Common Stock. F1 · ownership.nature: The reporting persons are EcoR1 Capital, LLC ("EcoR1"), Oleg Nodelman and EcoR1 Capital Fund Qualified L.P. ("Qualified Fund"). EcoR1 is the investment adviser and general partner of private funds, including Qualified Fund (collectively, the "Funds"). Mr. Nodelman is the manager and controlling owner of EcoR1. EcoR1 is filing this Form 4 for itself, Mr. Nodelman and Qualified Fund. The filers are filing this Form 4 jointly, but not as a group, and each expressly disclaims membership in a group within the meaning of Rule 13d-5(b) under the Securities Exchange Act of 1934. The Funds hold these securities directly for the benefit of their investors. EcoR1 may be deemed to indirectly beneficially own them as the investment adviser to the Funds. Mr. Nodelman may be deemed to indirectly beneficially own them as the control person of EcoR1. The filers disclaim beneficial ownership of such securities except to the extent of their pecuniary interests therein. Read SEC document |
| January 12, 2026 Filed Jan 13, 2026 01:28 UTC | Aktis Oncology, Inc. AKTS · Entity 4711 | ConversionClass A Common Stock · Derivative | 86,222 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000935836-26-000031 · ownership.xml · derivative · entry 12 EcoR1 Capital, LLC · CIK 0001587114 · Director NODELMAN OLEG · CIK 0001454385 · Director Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Note Disclosed balance after: 86,222 Underlying: Common Stock · 86,222 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_price: Each share of Class A Common Stock is convertible into one share of Common Stock at the election of the holder for no additional consideration, subject to a 4.99% beneficial ownership limitation. Each share is immediately exercisable and has no expiration date. F1 · price: The shares of Series A Redeemable Convertible Preferred Stock and Series B Redeemable Convertible Preferred Stock converted into shares of Common Stock and Class A Common Stock on a 3.8044-for-1 basis immediately prior to the closing of the initial public offering of the Issuer's Common Stock for no additional consideration. Each share was immediately exercisable and had no expiration date. F5 · derivative.exercise_date: Each share of Class A Common Stock is convertible into one share of Common Stock at the election of the holder for no additional consideration, subject to a 4.99% beneficial ownership limitation. Each share is immediately exercisable and has no expiration date. F5 · derivative.expiration_date: Each share of Class A Common Stock is convertible into one share of Common Stock at the election of the holder for no additional consideration, subject to a 4.99% beneficial ownership limitation. Each share is immediately exercisable and has no expiration date. F3 · ownership.nature: These securities are held by EcoR1 Capital Fund, L.P. ("Capital Fund"). EcoR1 may be deemed to indirectly beneficially own them as the investment adviser to and general partner of the fund. Mr. Nodelman may be deemed to indirectly beneficially own them as the control person of EcoR1. Read SEC document |
| January 12, 2026 Filed Jan 13, 2026 01:28 UTC | Aktis Oncology, Inc. AKTS · Entity 4711 | ConversionClass A Common Stock · Derivative | 965,190 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000935836-26-000031 · ownership.xml · derivative · entry 11 EcoR1 Capital, LLC · CIK 0001587114 · Director NODELMAN OLEG · CIK 0001454385 · Director Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See note Disclosed balance after: 965,190 Underlying: Common Stock · 965,190 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_price: Each share of Class A Common Stock is convertible into one share of Common Stock at the election of the holder for no additional consideration, subject to a 4.99% beneficial ownership limitation. Each share is immediately exercisable and has no expiration date. F1 · price: The shares of Series A Redeemable Convertible Preferred Stock and Series B Redeemable Convertible Preferred Stock converted into shares of Common Stock and Class A Common Stock on a 3.8044-for-1 basis immediately prior to the closing of the initial public offering of the Issuer's Common Stock for no additional consideration. Each share was immediately exercisable and had no expiration date. F5 · derivative.exercise_date: Each share of Class A Common Stock is convertible into one share of Common Stock at the election of the holder for no additional consideration, subject to a 4.99% beneficial ownership limitation. Each share is immediately exercisable and has no expiration date. F5 · derivative.expiration_date: Each share of Class A Common Stock is convertible into one share of Common Stock at the election of the holder for no additional consideration, subject to a 4.99% beneficial ownership limitation. Each share is immediately exercisable and has no expiration date. F2 · ownership.nature: These securities are held by EcoR1 Capital Fund Qualified, L.P. ("Qualified Fund"). EcoR1 Capital, LLC ("EcoR1") may be deemed to indirectly beneficially own them as the investment adviser to and general partner of the fund. Mr. Nodelman may be deemed to indirectly beneficially own them as the control person of EcoR1. Read SEC document |
| January 12, 2026 Filed Jan 13, 2026 01:28 UTC | Aktis Oncology, Inc. AKTS · Entity 4711 | ConversionSeries B Redeemable Convertible Preferred Stock · Derivative | 102,500 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000935836-26-000031 · ownership.xml · derivative · entry 10 EcoR1 Capital, LLC · CIK 0001587114 · Director NODELMAN OLEG · CIK 0001454385 · Director Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See note Disclosed balance after: 0 Underlying: Common Stock · 26,942 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The shares of Series A Redeemable Convertible Preferred Stock and Series B Redeemable Convertible Preferred Stock converted into shares of Common Stock and Class A Common Stock on a 3.8044-for-1 basis immediately prior to the closing of the initial public offering of the Issuer's Common Stock for no additional consideration. Each share was immediately exercisable and had no expiration date. F1 · price: The shares of Series A Redeemable Convertible Preferred Stock and Series B Redeemable Convertible Preferred Stock converted into shares of Common Stock and Class A Common Stock on a 3.8044-for-1 basis immediately prior to the closing of the initial public offering of the Issuer's Common Stock for no additional consideration. Each share was immediately exercisable and had no expiration date. F1 · derivative.exercise_date: The shares of Series A Redeemable Convertible Preferred Stock and Series B Redeemable Convertible Preferred Stock converted into shares of Common Stock and Class A Common Stock on a 3.8044-for-1 basis immediately prior to the closing of the initial public offering of the Issuer's Common Stock for no additional consideration. Each share was immediately exercisable and had no expiration date. F1 · derivative.expiration_date: The shares of Series A Redeemable Convertible Preferred Stock and Series B Redeemable Convertible Preferred Stock converted into shares of Common Stock and Class A Common Stock on a 3.8044-for-1 basis immediately prior to the closing of the initial public offering of the Issuer's Common Stock for no additional consideration. Each share was immediately exercisable and had no expiration date. F3 · ownership.nature: These securities are held by EcoR1 Capital Fund, L.P. ("Capital Fund"). EcoR1 may be deemed to indirectly beneficially own them as the investment adviser to and general partner of the fund. Mr. Nodelman may be deemed to indirectly beneficially own them as the control person of EcoR1. Read SEC document |
| January 12, 2026 Filed Jan 13, 2026 01:28 UTC | Aktis Oncology, Inc. AKTS · Entity 4711 | ConversionSeries B Redeemable Convertible Preferred Stock · Derivative | 2,397,500 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000935836-26-000031 · ownership.xml · derivative · entry 9 EcoR1 Capital, LLC · CIK 0001587114 · Director NODELMAN OLEG · CIK 0001454385 · Director Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See note Disclosed balance after: 0 Underlying: Common Stock · 630,191 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The shares of Series A Redeemable Convertible Preferred Stock and Series B Redeemable Convertible Preferred Stock converted into shares of Common Stock and Class A Common Stock on a 3.8044-for-1 basis immediately prior to the closing of the initial public offering of the Issuer's Common Stock for no additional consideration. Each share was immediately exercisable and had no expiration date. F1 · price: The shares of Series A Redeemable Convertible Preferred Stock and Series B Redeemable Convertible Preferred Stock converted into shares of Common Stock and Class A Common Stock on a 3.8044-for-1 basis immediately prior to the closing of the initial public offering of the Issuer's Common Stock for no additional consideration. Each share was immediately exercisable and had no expiration date. F1 · derivative.exercise_date: The shares of Series A Redeemable Convertible Preferred Stock and Series B Redeemable Convertible Preferred Stock converted into shares of Common Stock and Class A Common Stock on a 3.8044-for-1 basis immediately prior to the closing of the initial public offering of the Issuer's Common Stock for no additional consideration. Each share was immediately exercisable and had no expiration date. F1 · derivative.expiration_date: The shares of Series A Redeemable Convertible Preferred Stock and Series B Redeemable Convertible Preferred Stock converted into shares of Common Stock and Class A Common Stock on a 3.8044-for-1 basis immediately prior to the closing of the initial public offering of the Issuer's Common Stock for no additional consideration. Each share was immediately exercisable and had no expiration date. F2 · ownership.nature: These securities are held by EcoR1 Capital Fund Qualified, L.P. ("Qualified Fund"). EcoR1 Capital, LLC ("EcoR1") may be deemed to indirectly beneficially own them as the investment adviser to and general partner of the fund. Mr. Nodelman may be deemed to indirectly beneficially own them as the control person of EcoR1. Read SEC document |
| January 12, 2026 Filed Jan 13, 2026 01:28 UTC | Aktis Oncology, Inc. AKTS · Entity 4711 | ConversionSeries A Redeemable Convertible Preferred Stock · Derivative | 488,891 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000935836-26-000031 · ownership.xml · derivative · entry 8 EcoR1 Capital, LLC · CIK 0001587114 · Director NODELMAN OLEG · CIK 0001454385 · Director Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See note Disclosed balance after: 0 Underlying: Common Stock · 128,506 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The shares of Series A Redeemable Convertible Preferred Stock and Series B Redeemable Convertible Preferred Stock converted into shares of Common Stock and Class A Common Stock on a 3.8044-for-1 basis immediately prior to the closing of the initial public offering of the Issuer's Common Stock for no additional consideration. Each share was immediately exercisable and had no expiration date. F1 · price: The shares of Series A Redeemable Convertible Preferred Stock and Series B Redeemable Convertible Preferred Stock converted into shares of Common Stock and Class A Common Stock on a 3.8044-for-1 basis immediately prior to the closing of the initial public offering of the Issuer's Common Stock for no additional consideration. Each share was immediately exercisable and had no expiration date. F1 · derivative.exercise_date: The shares of Series A Redeemable Convertible Preferred Stock and Series B Redeemable Convertible Preferred Stock converted into shares of Common Stock and Class A Common Stock on a 3.8044-for-1 basis immediately prior to the closing of the initial public offering of the Issuer's Common Stock for no additional consideration. Each share was immediately exercisable and had no expiration date. F1 · derivative.expiration_date: The shares of Series A Redeemable Convertible Preferred Stock and Series B Redeemable Convertible Preferred Stock converted into shares of Common Stock and Class A Common Stock on a 3.8044-for-1 basis immediately prior to the closing of the initial public offering of the Issuer's Common Stock for no additional consideration. Each share was immediately exercisable and had no expiration date. F4 · ownership.nature: These securities are held by EcoR1 Venture Opportunity Fund, L.P. ("Venture Fund"). EcoR1 may be deemed to indirectly beneficially own them as the investment adviser to and general partner of the fund. Mr. Nodelman may be deemed to indirectly beneficially own them as the control person of EcoR1. Read SEC document |
| January 12, 2026 Filed Jan 13, 2026 01:28 UTC | Aktis Oncology, Inc. AKTS · Entity 4711 | ConversionSeries A Redeemable Convertible Preferred Stock · Derivative | 997,299 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000935836-26-000031 · ownership.xml · derivative · entry 7 EcoR1 Capital, LLC · CIK 0001587114 · Director NODELMAN OLEG · CIK 0001454385 · Director Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See note Disclosed balance after: 0 Underlying: Common Stock · 262,142 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The shares of Series A Redeemable Convertible Preferred Stock and Series B Redeemable Convertible Preferred Stock converted into shares of Common Stock and Class A Common Stock on a 3.8044-for-1 basis immediately prior to the closing of the initial public offering of the Issuer's Common Stock for no additional consideration. Each share was immediately exercisable and had no expiration date. F1 · price: The shares of Series A Redeemable Convertible Preferred Stock and Series B Redeemable Convertible Preferred Stock converted into shares of Common Stock and Class A Common Stock on a 3.8044-for-1 basis immediately prior to the closing of the initial public offering of the Issuer's Common Stock for no additional consideration. Each share was immediately exercisable and had no expiration date. F1 · derivative.exercise_date: The shares of Series A Redeemable Convertible Preferred Stock and Series B Redeemable Convertible Preferred Stock converted into shares of Common Stock and Class A Common Stock on a 3.8044-for-1 basis immediately prior to the closing of the initial public offering of the Issuer's Common Stock for no additional consideration. Each share was immediately exercisable and had no expiration date. F1 · derivative.expiration_date: The shares of Series A Redeemable Convertible Preferred Stock and Series B Redeemable Convertible Preferred Stock converted into shares of Common Stock and Class A Common Stock on a 3.8044-for-1 basis immediately prior to the closing of the initial public offering of the Issuer's Common Stock for no additional consideration. Each share was immediately exercisable and had no expiration date. F3 · ownership.nature: These securities are held by EcoR1 Capital Fund, L.P. ("Capital Fund"). EcoR1 may be deemed to indirectly beneficially own them as the investment adviser to and general partner of the fund. Mr. Nodelman may be deemed to indirectly beneficially own them as the control person of EcoR1. Read SEC document |
| January 12, 2026 Filed Jan 13, 2026 01:28 UTC | Aktis Oncology, Inc. AKTS · Entity 4711 | ConversionSeries A Redeemable Convertible Preferred Stock · Derivative | 9,913,810 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000935836-26-000031 · ownership.xml · derivative · entry 6 EcoR1 Capital, LLC · CIK 0001587114 · Director NODELMAN OLEG · CIK 0001454385 · Director Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See note Disclosed balance after: 0 Underlying: Common Stock · 2,605,878 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The shares of Series A Redeemable Convertible Preferred Stock and Series B Redeemable Convertible Preferred Stock converted into shares of Common Stock and Class A Common Stock on a 3.8044-for-1 basis immediately prior to the closing of the initial public offering of the Issuer's Common Stock for no additional consideration. Each share was immediately exercisable and had no expiration date. F1 · price: The shares of Series A Redeemable Convertible Preferred Stock and Series B Redeemable Convertible Preferred Stock converted into shares of Common Stock and Class A Common Stock on a 3.8044-for-1 basis immediately prior to the closing of the initial public offering of the Issuer's Common Stock for no additional consideration. Each share was immediately exercisable and had no expiration date. F1 · derivative.exercise_date: The shares of Series A Redeemable Convertible Preferred Stock and Series B Redeemable Convertible Preferred Stock converted into shares of Common Stock and Class A Common Stock on a 3.8044-for-1 basis immediately prior to the closing of the initial public offering of the Issuer's Common Stock for no additional consideration. Each share was immediately exercisable and had no expiration date. F1 · derivative.expiration_date: The shares of Series A Redeemable Convertible Preferred Stock and Series B Redeemable Convertible Preferred Stock converted into shares of Common Stock and Class A Common Stock on a 3.8044-for-1 basis immediately prior to the closing of the initial public offering of the Issuer's Common Stock for no additional consideration. Each share was immediately exercisable and had no expiration date. F2 · ownership.nature: These securities are held by EcoR1 Capital Fund Qualified, L.P. ("Qualified Fund"). EcoR1 Capital, LLC ("EcoR1") may be deemed to indirectly beneficially own them as the investment adviser to and general partner of the fund. Mr. Nodelman may be deemed to indirectly beneficially own them as the control person of EcoR1. Read SEC document |
| January 12, 2026 Filed Jan 13, 2026 01:28 UTC | Aktis Oncology, Inc. AKTS · Entity 4711 | PurchaseCommon Stock | 144,443 | $18.00 | $2,599,974.00 |
DisclosureSEC source: 0000935836-26-000031 · ownership.xml · nonDerivative · entry 5 EcoR1 Capital, LLC · CIK 0001587114 · Director NODELMAN OLEG · CIK 0001454385 · Director Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Note Disclosed balance after: 347,305 F3 · ownership.nature: These securities are held by EcoR1 Capital Fund, L.P. ("Capital Fund"). EcoR1 may be deemed to indirectly beneficially own them as the investment adviser to and general partner of the fund. Mr. Nodelman may be deemed to indirectly beneficially own them as the control person of EcoR1. Read SEC document |
| January 12, 2026 Filed Jan 13, 2026 01:28 UTC | Aktis Oncology, Inc. AKTS · Entity 4711 | PurchaseCommon Stock | 2,077,779 | $18.00 | $37,400,022.00 |
DisclosureSEC source: 0000935836-26-000031 · ownership.xml · nonDerivative · entry 4 EcoR1 Capital, LLC · CIK 0001587114 · Director NODELMAN OLEG · CIK 0001454385 · Director Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Note Disclosed balance after: 4,348,658 F2 · ownership.nature: These securities are held by EcoR1 Capital Fund Qualified, L.P. ("Qualified Fund"). EcoR1 Capital, LLC ("EcoR1") may be deemed to indirectly beneficially own them as the investment adviser to and general partner of the fund. Mr. Nodelman may be deemed to indirectly beneficially own them as the control person of EcoR1. Read SEC document |
| January 12, 2026 Filed Jan 13, 2026 01:28 UTC | Aktis Oncology, Inc. AKTS · Entity 4711 | ConversionCommon Stock | 128,506 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000935836-26-000031 · ownership.xml · nonDerivative · entry 3 EcoR1 Capital, LLC · CIK 0001587114 · Director NODELMAN OLEG · CIK 0001454385 · Director Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Note Disclosed balance after: 128,506 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The shares of Series A Redeemable Convertible Preferred Stock and Series B Redeemable Convertible Preferred Stock converted into shares of Common Stock and Class A Common Stock on a 3.8044-for-1 basis immediately prior to the closing of the initial public offering of the Issuer's Common Stock for no additional consideration. Each share was immediately exercisable and had no expiration date. F4 · ownership.nature: These securities are held by EcoR1 Venture Opportunity Fund, L.P. ("Venture Fund"). EcoR1 may be deemed to indirectly beneficially own them as the investment adviser to and general partner of the fund. Mr. Nodelman may be deemed to indirectly beneficially own them as the control person of EcoR1. Read SEC document |
| January 12, 2026 Filed Jan 13, 2026 01:28 UTC | Aktis Oncology, Inc. AKTS · Entity 4711 | ConversionCommon Stock | 202,862 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000935836-26-000031 · ownership.xml · nonDerivative · entry 2 EcoR1 Capital, LLC · CIK 0001587114 · Director NODELMAN OLEG · CIK 0001454385 · Director Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Note Disclosed balance after: 202,862 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The shares of Series A Redeemable Convertible Preferred Stock and Series B Redeemable Convertible Preferred Stock converted into shares of Common Stock and Class A Common Stock on a 3.8044-for-1 basis immediately prior to the closing of the initial public offering of the Issuer's Common Stock for no additional consideration. Each share was immediately exercisable and had no expiration date. F3 · ownership.nature: These securities are held by EcoR1 Capital Fund, L.P. ("Capital Fund"). EcoR1 may be deemed to indirectly beneficially own them as the investment adviser to and general partner of the fund. Mr. Nodelman may be deemed to indirectly beneficially own them as the control person of EcoR1. Read SEC document |
| January 12, 2026 Filed Jan 13, 2026 01:28 UTC | Aktis Oncology, Inc. AKTS · Entity 4711 | ConversionCommon Stock | 2,270,879 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000935836-26-000031 · ownership.xml · nonDerivative · entry 1 EcoR1 Capital, LLC · CIK 0001587114 · Director NODELMAN OLEG · CIK 0001454385 · Director Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Note Disclosed balance after: 2,270,879 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The shares of Series A Redeemable Convertible Preferred Stock and Series B Redeemable Convertible Preferred Stock converted into shares of Common Stock and Class A Common Stock on a 3.8044-for-1 basis immediately prior to the closing of the initial public offering of the Issuer's Common Stock for no additional consideration. Each share was immediately exercisable and had no expiration date. F2 · ownership.nature: These securities are held by EcoR1 Capital Fund Qualified, L.P. ("Qualified Fund"). EcoR1 Capital, LLC ("EcoR1") may be deemed to indirectly beneficially own them as the investment adviser to and general partner of the fund. Mr. Nodelman may be deemed to indirectly beneficially own them as the control person of EcoR1. Read SEC document |
| July 30, 2025 Filed Jul 30, 2025 22:20 UTC | Adaptimmune Therapeutics PLC ADAP · Entity 9824 | SaleOrdinary Shares | 27,433,338 | $0.10 | $2,800,943.81 |
DisclosureSEC source: 0000935836-25-000476 · ownership.xml · nonDerivative · entry 3 EcoR1 Capital, LLC · CIK 0001587114 · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · See Note Disclosed balance after: 100,371,882 F1 · security: These Ordinary Shares are held through American Depositary Shares ("ADS") of the Issuer. Each ADS represents 6 Ordinary Shares. F9 · shares: The reporting persons sold 4,572,223 ADSs representing 27,433,338 Ordinary Shares. Qualified Fund sold 4,270,000 of those ADSs, representing 25,620,000 Ordinary Shares. F7 · price: The price reported in Column 4 is the price per ADS sold by the reporting persons. F10 · balance_after: After this transaction, the reporting persons beneficially owned 16,728,647 ADSs, including 15,881,331 ADSs held by Qualified Fund representing 95,287,986 Ordinary Shares. F2 · ownership.nature: The reporting persons are EcoR1 Capital, LLC ("Ecor1"), Oleg Nodelman and EcoR1 Capital Fund Qualified, L.P. ("Qualified Fund"). EcoR1 is the general partner and investment adviser of private funds, including Qualified Fund (the "Fund"). Mr. Nodelman is the manager and controlling owner of EcoR1. EcoR1 is filing this Form 4 for itself, Mr. Nodelman and Qualified Fund. The filers are filing this Form 4 jointly, but not as a group, and each expressly disclaims membership in a group within the meaning of Rule 13d-5(b) under the Securities Exchange Act of 1934. The Funds hold these securities directly for the benefit of their investors. EcoR1 may be deemed to indirectly beneficially own them as the investment adviser to the Funds. Mr. Nodelman may be deemed to indirectly beneficially own them as the control person of EcoR1. The filers disclaim beneficial ownership of the securities except to the extent of their respective pecuniary interests therein. Read SEC document |
| July 29, 2025 Filed Jul 30, 2025 22:20 UTC | Adaptimmune Therapeutics PLC ADAP · Entity 9824 | SaleOrdinary Shares | 2,687,460 | $0.10 | $271,970.95 |
DisclosureSEC source: 0000935836-25-000476 · ownership.xml · nonDerivative · entry 2 EcoR1 Capital, LLC · CIK 0001587114 · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · See Note Disclosed balance after: 127,805,220 F1 · security: These Ordinary Shares are held through American Depositary Shares ("ADS") of the Issuer. Each ADS represents 6 Ordinary Shares. F6 · shares: The reporting persons sold 447,910 ADSs representing 2,687,460 Ordinary Shares. Qualified Fund sold 418,303 of those ADSs, representing 2,509,818 Ordinary Shares. F7 · price: The price reported in Column 4 is the price per ADS sold by the reporting persons. F8 · balance_after: After this transaction, the reporting persons beneficially owned 21,300,870 ADSs, including 20,151,331 ADSs held by Qualified Fund representing 120,907,986 Ordinary Shares. F2 · ownership.nature: The reporting persons are EcoR1 Capital, LLC ("Ecor1"), Oleg Nodelman and EcoR1 Capital Fund Qualified, L.P. ("Qualified Fund"). EcoR1 is the general partner and investment adviser of private funds, including Qualified Fund (the "Fund"). Mr. Nodelman is the manager and controlling owner of EcoR1. EcoR1 is filing this Form 4 for itself, Mr. Nodelman and Qualified Fund. The filers are filing this Form 4 jointly, but not as a group, and each expressly disclaims membership in a group within the meaning of Rule 13d-5(b) under the Securities Exchange Act of 1934. The Funds hold these securities directly for the benefit of their investors. EcoR1 may be deemed to indirectly beneficially own them as the investment adviser to the Funds. Mr. Nodelman may be deemed to indirectly beneficially own them as the control person of EcoR1. The filers disclaim beneficial ownership of the securities except to the extent of their respective pecuniary interests therein. Read SEC document |
| July 28, 2025 Filed Jul 30, 2025 22:20 UTC | Adaptimmune Therapeutics PLC ADAP · Entity 9824 | SaleOrdinary Shares | 33,931,740 | $0.11 | $3,817,320.75 |
DisclosureSEC source: 0000935836-25-000476 · ownership.xml · nonDerivative · entry 1 EcoR1 Capital, LLC · CIK 0001587114 · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · See Note Disclosed balance after: 130,492,680 F1 · security: These Ordinary Shares are held through American Depositary Shares ("ADS") of the Issuer. Each ADS represents 6 Ordinary Shares. F3 · shares: The reporting persons sold 5,655,290 ADSs representing 33,931,740 Ordinary Shares. Qualified Fund sold 5,281,476 of those ADSs, representing 31,688,856 Ordinary Shares. F4 · price: The price reported in Column 4 is the price per ADS sold by the reporting persons. This price is a weighted average price. These ADSs were sold in multiple transactions at prices ranging from $0.1086 to $0.1184, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of ADSs sold at each separate price within the ranges set forth in this footnote. F5 · balance_after: After this transaction, the reporting persons beneficially owned 21,748,780 ADSs, including 20,569,634 ADS held by Qualified Fund representing 123,417,804 Ordinary Shares. F2 · ownership.nature: The reporting persons are EcoR1 Capital, LLC ("Ecor1"), Oleg Nodelman and EcoR1 Capital Fund Qualified, L.P. ("Qualified Fund"). EcoR1 is the general partner and investment adviser of private funds, including Qualified Fund (the "Fund"). Mr. Nodelman is the manager and controlling owner of EcoR1. EcoR1 is filing this Form 4 for itself, Mr. Nodelman and Qualified Fund. The filers are filing this Form 4 jointly, but not as a group, and each expressly disclaims membership in a group within the meaning of Rule 13d-5(b) under the Securities Exchange Act of 1934. The Funds hold these securities directly for the benefit of their investors. EcoR1 may be deemed to indirectly beneficially own them as the investment adviser to the Funds. Mr. Nodelman may be deemed to indirectly beneficially own them as the control person of EcoR1. The filers disclaim beneficial ownership of the securities except to the extent of their respective pecuniary interests therein. Read SEC document |
| June 26, 2025 Filed Jun 27, 2025 17:50 UTC | Zymeworks Inc. ZYME · Entity 4458 | OtherPre-Funded Warrants (right to acquire) · Derivative | 5,086,521 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000935836-25-000438 · ownership.xml · derivative · entry 3 EcoR1 Capital, LLC · CIK 0001587114 · Director · 10% owner NODELMAN OLEG · CIK 0001454385 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See note Disclosed balance after: 0 Underlying: Common Stock · 5,086,521 shares Expires not disclosed F5 · shares: Qualified Fund exercised 4,818,462 of the pre-funded warrants reported in this transaction. F6 · derivative.expiration_date: The pre-funded warrants did not have an expiration date. F1 · ownership.nature: The reporting persons are EcoR1 Capital, LLC ("EcoR1"), Oleg Nodelman and EcoR1 Capital Fund Qualified, L.P. ("Qualified Fund"). EcoR1 is the general partner and investment adviser of private funds, including Qualified Fund (the "Funds"). Mr. Nodelman is the manager and controlling owner of EcoR1. EcoR1 is filing this Form 4 for itself and Qualified Fund. The filers are filing this Form 4 jointly, but not as a group, and each expressly disclaims membership in a group within the meaning of Rule 13d-5(b) under the Securities Exchange Act of 1934. The Funds hold these securities directly for the benefit of their investors. EcoR1 may be deemed to indirectly beneficially own them as the investment adviser to the Funds. Mr. Nodelman may be deemed to indirectly beneficially own them as the control person of EcoR1. The filers disclaim beneficial ownership of the securities except to the extent of their respective pecuniary interests therein. Read SEC document |
| June 26, 2025 Filed Jun 27, 2025 17:50 UTC | Zymeworks Inc. ZYME · Entity 4458 | Tax withholdingCommon Stock | 41 | $12.71 | $521.11 |
DisclosureSEC source: 0000935836-25-000438 · ownership.xml · nonDerivative · entry 2 EcoR1 Capital, LLC · CIK 0001587114 · Director · 10% owner NODELMAN OLEG · CIK 0001454385 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Note Disclosed balance after: 22,970,388 F4 · kind: On June 26, 2025,the reporting persons exercised pre-funded warrants to purchase 5,086,521 shares of the Issuer's Common Stock for $0.0001 per share. The reporting persons paid the exercise price on a cashless basis, resulting in the Issuer withholding 41 of the warrant shares (including 38 warrant shares issuable to Qualified Fund) to pay the exercise price and issuing to the reporting persons the remaining 5,086,480 shares. F3 · balance_after: After the transactions reported herein, Qualified Fund held 21,582,563 shares of the Issuer's Common Stock. F1 · ownership.nature: The reporting persons are EcoR1 Capital, LLC ("EcoR1"), Oleg Nodelman and EcoR1 Capital Fund Qualified, L.P. ("Qualified Fund"). EcoR1 is the general partner and investment adviser of private funds, including Qualified Fund (the "Funds"). Mr. Nodelman is the manager and controlling owner of EcoR1. EcoR1 is filing this Form 4 for itself and Qualified Fund. The filers are filing this Form 4 jointly, but not as a group, and each expressly disclaims membership in a group within the meaning of Rule 13d-5(b) under the Securities Exchange Act of 1934. The Funds hold these securities directly for the benefit of their investors. EcoR1 may be deemed to indirectly beneficially own them as the investment adviser to the Funds. Mr. Nodelman may be deemed to indirectly beneficially own them as the control person of EcoR1. The filers disclaim beneficial ownership of the securities except to the extent of their respective pecuniary interests therein. Read SEC document |
| June 26, 2025 Filed Jun 27, 2025 17:50 UTC | Zymeworks Inc. ZYME · Entity 4458 | OtherCommon Stock | 5,086,480 | $0.00 | $508.65 |
DisclosureSEC source: 0000935836-25-000438 · ownership.xml · nonDerivative · entry 1 EcoR1 Capital, LLC · CIK 0001587114 · Director · 10% owner NODELMAN OLEG · CIK 0001454385 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Note Disclosed balance after: 22,970,388 F2 · shares: Qualified Fund acquired 4,818,424 shares of Common Stock in connection with the exercise of the pre-funded warrants. F3 · balance_after: After the transactions reported herein, Qualified Fund held 21,582,563 shares of the Issuer's Common Stock. F1 · ownership.nature: The reporting persons are EcoR1 Capital, LLC ("EcoR1"), Oleg Nodelman and EcoR1 Capital Fund Qualified, L.P. ("Qualified Fund"). EcoR1 is the general partner and investment adviser of private funds, including Qualified Fund (the "Funds"). Mr. Nodelman is the manager and controlling owner of EcoR1. EcoR1 is filing this Form 4 for itself and Qualified Fund. The filers are filing this Form 4 jointly, but not as a group, and each expressly disclaims membership in a group within the meaning of Rule 13d-5(b) under the Securities Exchange Act of 1934. The Funds hold these securities directly for the benefit of their investors. EcoR1 may be deemed to indirectly beneficially own them as the investment adviser to the Funds. Mr. Nodelman may be deemed to indirectly beneficially own them as the control person of EcoR1. The filers disclaim beneficial ownership of the securities except to the extent of their respective pecuniary interests therein. Read SEC document |
| May 19, 2025 Filed May 19, 2025 18:35 UTC | Zymeworks Inc. ZYME · Entity 4458 | PurchaseCommon Stock | 5,919 | $11.78 | $69,738.25 |
DisclosureSEC source: 0000935836-25-000389 · ownership.xml · nonDerivative · entry 2 EcoR1 Capital, LLC · CIK 0001587114 · Director · 10% owner NODELMAN OLEG · CIK 0001454385 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Note Disclosed balance after: 17,883,908 F4 · shares: Qualified Fund purchased 5,550 of the shares purchased in this transaction. F5 · balance_after: After this transaction, Qualified Fund held 16,764,139 shares of the Issuer's Common Stock. F1 · ownership.nature: The reporting persons are EcoR1 Capital, LLC ("EcoR1"), Oleg Nodelman and EcoR1 Capital Fund Qualified, L.P. ("Qualified Fund"). EcoR1 is the general partner and investment adviser of private funds, including Qualified Fund (the "Funds"). Mr. Nodelman is the manager and controlling owner of EcoR1. EcoR1 is filing this Form 4 for itself and Qualified Fund. The filers are filing this Form 4 jointly, but not as a group, and each expressly disclaims membership in a group within the meaning of Rule 13d-5(b) under the Securities Exchange Act of 1934. The Funds hold these securities directly for the benefit of their investors. EcoR1 may be deemed to indirectly beneficially own them as the investment adviser to the Funds. Mr. Nodelman may be deemed to indirectly beneficially own them as the control person of EcoR1. The filers disclaim beneficial ownership of the securities except to the extent of their respective pecuniary interests therein. Read SEC document |
| May 15, 2025 Filed May 16, 2025 18:52 UTC | iTeos Therapeutics, Inc. ITOS · Entity 75965 | PurchaseCommon Stock | 3,300,000 | $8.00 | $26,400,000.00 |
DisclosureSEC source: 0000935836-25-000384 · ownership.xml · nonDerivative · entry 2 EcoR1 Capital, LLC · CIK 0001587114 · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · See Note Disclosed balance after: 10,688,978 F5 · shares: Qualified Fund purchased 3,093,422 of the shares purchased in this transaction. F6 · balance_after: After this transaction, Qualified Fund held 10,020,210 shares of the Issuer's Common Stock. F1 · ownership.nature: The reporting persons are EcoR1 Capital, LLC ("Ecor1"), Oleg Nodelman and EcoR1 Capital Fund Qualified, L.P. ("Qualified Fund"). EcoR1 is the general partner and investment adviser of private funds, including Qualified Fund (the "Funds"). Mr. Nodelman is the manager and controlling owner of EcoR1. EcoR1 is filing this Form 4 for itself, Mr. Nodelman and Qualified Fund. The filers are filing this Form 4 jointly, but not as a group, and each expressly disclaims membership in a group within the meaning of Rule 13d-5(b) under the Securities Exchange Act of 1934. The Funds hold these securities directly for the benefit of their investors. EcoR1 may be deemed to indirectly beneficially own them as the investment adviser to the Funds. Mr. Nodelman may be deemed to indirectly beneficially own them as the control person of EcoR1. The filers disclaim beneficial ownership of the securities except to the extent of their respective pecuniary interests therein. Read SEC document |
| May 15, 2025 Filed May 19, 2025 18:35 UTC | Zymeworks Inc. ZYME · Entity 4458 | PurchaseCommon Stock | 49,502 | $11.43 | $565,847.46 |
DisclosureSEC source: 0000935836-25-000389 · ownership.xml · nonDerivative · entry 1 EcoR1 Capital, LLC · CIK 0001587114 · Director · 10% owner NODELMAN OLEG · CIK 0001454385 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Note Disclosed balance after: 17,877,989 F2 · shares: Qualified Fund purchased 46,405 of the shares purchased in this transaction. F3 · balance_after: After this transaction, Qualified Fund held 16,758,589 shares of the Issuer's Common Stock. F1 · ownership.nature: The reporting persons are EcoR1 Capital, LLC ("EcoR1"), Oleg Nodelman and EcoR1 Capital Fund Qualified, L.P. ("Qualified Fund"). EcoR1 is the general partner and investment adviser of private funds, including Qualified Fund (the "Funds"). Mr. Nodelman is the manager and controlling owner of EcoR1. EcoR1 is filing this Form 4 for itself and Qualified Fund. The filers are filing this Form 4 jointly, but not as a group, and each expressly disclaims membership in a group within the meaning of Rule 13d-5(b) under the Securities Exchange Act of 1934. The Funds hold these securities directly for the benefit of their investors. EcoR1 may be deemed to indirectly beneficially own them as the investment adviser to the Funds. Mr. Nodelman may be deemed to indirectly beneficially own them as the control person of EcoR1. The filers disclaim beneficial ownership of the securities except to the extent of their respective pecuniary interests therein. Read SEC document |
| May 14, 2025 Filed May 16, 2025 18:52 UTC | iTeos Therapeutics, Inc. ITOS · Entity 75965 | PurchaseCommon Stock | 1,658,978 | $7.41 | $12,285,561.58 |
DisclosureSEC source: 0000935836-25-000384 · ownership.xml · nonDerivative · entry 1 EcoR1 Capital, LLC · CIK 0001587114 · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · See Note Disclosed balance after: 7,388,978 F2 · shares: Qualified Fund purchased 1,555,127 of the shares purchased in this transaction. F3 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $7.35 to $7.60, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote. F4 · balance_after: After this transaction, Qualified Fund held 6,926,788 shares of the Issuer's Common Stock. F1 · ownership.nature: The reporting persons are EcoR1 Capital, LLC ("Ecor1"), Oleg Nodelman and EcoR1 Capital Fund Qualified, L.P. ("Qualified Fund"). EcoR1 is the general partner and investment adviser of private funds, including Qualified Fund (the "Funds"). Mr. Nodelman is the manager and controlling owner of EcoR1. EcoR1 is filing this Form 4 for itself, Mr. Nodelman and Qualified Fund. The filers are filing this Form 4 jointly, but not as a group, and each expressly disclaims membership in a group within the meaning of Rule 13d-5(b) under the Securities Exchange Act of 1934. The Funds hold these securities directly for the benefit of their investors. EcoR1 may be deemed to indirectly beneficially own them as the investment adviser to the Funds. Mr. Nodelman may be deemed to indirectly beneficially own them as the control person of EcoR1. The filers disclaim beneficial ownership of the securities except to the extent of their respective pecuniary interests therein. Read SEC document |
| May 06, 2025 Filed May 6, 2025 23:06 UTC | PROTHENA CORP PUBLIC LTD CO PRTA · Entity 2375 | SaleOrdinary Shares | 1,984,053 | $7.64 | $15,164,712.29 |
DisclosureSEC source: 0000935836-25-000309 · ownership.xml · nonDerivative · entry 3 EcoR1 Capital, LLC · CIK 0001587114 · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · See Note Disclosed balance after: 5,304,596 F8 · shares: Qualified Fund sold 1,859,851 of the shares sold in this transaction. F9 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.4637 to $8.5939, inclusive. F10 · balance_after: After this transaction, Qualified Fund held 4,973,891 of the Issuer's Ordinary Shares. F1 · ownership.nature: The reporting persons are EcoR1 Capital, LLC ("Ecor1"), Oleg Nodelman and EcoR1 Capital Fund Qualified, L.P. ("Qualified Fund"). EcoR1 is the general partner and investment adviser of private funds, including Qualified Fund (the "Fund"). Mr. Nodelman is the manager and controlling owner of EcoR1. EcoR1 is filing this Form 4 for itself, Mr. Nodelman and Qualified Fund. The filers are filing this Form 4 jointly, but not as a group, and each expressly disclaims membership in a group within the meaning of Rule 13d-5(b) under the Securities Exchange Act of 1934. The Funds hold these securities directly for the benefit of their investors. EcoR1 may be deemed to indirectly beneficially own them as the investment adviser to the Funds. Mr. Nodelman may be deemed to indirectly beneficially own them as the control person of EcoR1. The filers disclaim beneficial ownership of the securities except to the extent of their respective pecuniary interests therein. Read SEC document |
| May 05, 2025 Filed May 6, 2025 23:06 UTC | PROTHENA CORP PUBLIC LTD CO PRTA · Entity 2375 | SaleOrdinary Shares | 977,693 | $8.11 | $7,930,165.69 |
DisclosureSEC source: 0000935836-25-000309 · ownership.xml · nonDerivative · entry 2 EcoR1 Capital, LLC · CIK 0001587114 · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · See Note Disclosed balance after: 7,288,649 F5 · shares: Qualified Fund sold 916,492 of the shares of sold in this transaction. F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.1097 to $8.1972, inclusive. F7 · balance_after: After this transaction, Qualified Fund held 6,833,742 shares of the Issuer's Common Stock F1 · ownership.nature: The reporting persons are EcoR1 Capital, LLC ("Ecor1"), Oleg Nodelman and EcoR1 Capital Fund Qualified, L.P. ("Qualified Fund"). EcoR1 is the general partner and investment adviser of private funds, including Qualified Fund (the "Fund"). Mr. Nodelman is the manager and controlling owner of EcoR1. EcoR1 is filing this Form 4 for itself, Mr. Nodelman and Qualified Fund. The filers are filing this Form 4 jointly, but not as a group, and each expressly disclaims membership in a group within the meaning of Rule 13d-5(b) under the Securities Exchange Act of 1934. The Funds hold these securities directly for the benefit of their investors. EcoR1 may be deemed to indirectly beneficially own them as the investment adviser to the Funds. Mr. Nodelman may be deemed to indirectly beneficially own them as the control person of EcoR1. The filers disclaim beneficial ownership of the securities except to the extent of their respective pecuniary interests therein. Read SEC document |
| May 02, 2025 Filed May 6, 2025 23:06 UTC | PROTHENA CORP PUBLIC LTD CO PRTA · Entity 2375 | SaleOrdinary Shares | 3,317,938 | $8.36 | $27,744,929.35 |
DisclosureSEC source: 0000935836-25-000309 · ownership.xml · nonDerivative · entry 1 EcoR1 Capital, LLC · CIK 0001587114 · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · See Note Disclosed balance after: 8,266,342 F2 · shares: Qualified Fund sold 3,097,619 of the shares sold in this transaction. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.2715 to $9.1789, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each seperate price within the ranges set forth in this footnote and footnotes 6 and 9. F4 · balance_after: After this transaction, Qualified Fund held 7,750,234 shares of the Issuer's Common Stock. F1 · ownership.nature: The reporting persons are EcoR1 Capital, LLC ("Ecor1"), Oleg Nodelman and EcoR1 Capital Fund Qualified, L.P. ("Qualified Fund"). EcoR1 is the general partner and investment adviser of private funds, including Qualified Fund (the "Fund"). Mr. Nodelman is the manager and controlling owner of EcoR1. EcoR1 is filing this Form 4 for itself, Mr. Nodelman and Qualified Fund. The filers are filing this Form 4 jointly, but not as a group, and each expressly disclaims membership in a group within the meaning of Rule 13d-5(b) under the Securities Exchange Act of 1934. The Funds hold these securities directly for the benefit of their investors. EcoR1 may be deemed to indirectly beneficially own them as the investment adviser to the Funds. Mr. Nodelman may be deemed to indirectly beneficially own them as the control person of EcoR1. The filers disclaim beneficial ownership of the securities except to the extent of their respective pecuniary interests therein. Read SEC document |
| April 17, 2025 Filed Apr 18, 2025 15:17 UTC | Zymeworks Inc. ZYME · Entity 4458 | PurchaseCommon Stock | 54,760 | $11.52 | $630,818.77 |
DisclosureSEC source: 0000935836-25-000292 · ownership.xml · nonDerivative · entry 2 EcoR1 Capital, LLC · CIK 0001587114 · Director · 10% owner NODELMAN OLEG · CIK 0001454385 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Note Disclosed balance after: 17,828,487 F5 · shares: Qualified Fund purchased 51,344 of the shares purchased in this transaction. F6 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $11.5125 to $11.5214, inclusive. F7 · balance_after: After this transaction, Qualified Fund held 16,712,184 shares of the Issuer's Common Stock. F1 · ownership.nature: The reporting persons are EcoR1 Capital, LLC ("EcoR1"), Oleg Nodelman and EcoR1 Capital Fund Qualified, L.P. ("Qualified Fund"). EcoR1 is the general partner and investment adviser of private funds, including Qualified Fund (the "Funds"). Mr. Nodelman is the manager and controlling owner of EcoR1. EcoR1 is filing this Form 4 for itself and Qualified Fund. The filers are filing this Form 4 jointly, but not as a group, and each expressly disclaims membership in a group within the meaning of Rule 13d-5(b) under the Securities Exchange Act of 1934. The Funds hold these securities directly for the benefit of their investors. EcoR1 may be deemed to indirectly beneficially own them as the investment adviser to the Funds. Mr. Nodelman may be deemed to indirectly beneficially own them as the control person of EcoR1. The filers disclaim beneficial ownership of the securities except to the extent of their respective pecuniary interests therein. Read SEC document |
| April 16, 2025 Filed Apr 18, 2025 15:17 UTC | Zymeworks Inc. ZYME · Entity 4458 | PurchaseCommon Stock | 73,953 | $11.16 | $825,589.11 |
DisclosureSEC source: 0000935836-25-000292 · ownership.xml · nonDerivative · entry 1 EcoR1 Capital, LLC · CIK 0001587114 · Director · 10% owner NODELMAN OLEG · CIK 0001454385 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Note Disclosed balance after: 17,773,727 F2 · shares: Qualified Fund purchased 69,339 of the shares purchased in this transaction. F3 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $10.9823 to $11.2339 inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each seperate price within the ranges set forth in this footnote and footnote 6. F4 · balance_after: After this transaction, Qualified Fund held 16,660,840 shares of the Issuer's Common Stock. F1 · ownership.nature: The reporting persons are EcoR1 Capital, LLC ("EcoR1"), Oleg Nodelman and EcoR1 Capital Fund Qualified, L.P. ("Qualified Fund"). EcoR1 is the general partner and investment adviser of private funds, including Qualified Fund (the "Funds"). Mr. Nodelman is the manager and controlling owner of EcoR1. EcoR1 is filing this Form 4 for itself and Qualified Fund. The filers are filing this Form 4 jointly, but not as a group, and each expressly disclaims membership in a group within the meaning of Rule 13d-5(b) under the Securities Exchange Act of 1934. The Funds hold these securities directly for the benefit of their investors. EcoR1 may be deemed to indirectly beneficially own them as the investment adviser to the Funds. Mr. Nodelman may be deemed to indirectly beneficially own them as the control person of EcoR1. The filers disclaim beneficial ownership of the securities except to the extent of their respective pecuniary interests therein. Read SEC document |
| April 04, 2025 Filed Apr 7, 2025 18:34 UTC | Zymeworks Inc. ZYME · Entity 4458 | PurchaseCommon Stock | 196,438 | $11.17 | $2,193,799.94 |
DisclosureSEC source: 0000935836-25-000266 · ownership.xml · nonDerivative · entry 2 EcoR1 Capital, LLC · CIK 0001587114 · Director · 10% owner NODELMAN OLEG · CIK 0001454385 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Note Disclosed balance after: 17,699,774 F5 · shares: Qualified Fund purchased 184,181 of the shares purchased in this transaction. F6 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $10.9804 to $11.2921, inclusive. F7 · balance_after: After this transaction, Qualified Fund held 16,591,501 shares of the Issuer's Common Stock. F1 · ownership.nature: The reporting persons are EcoR1 Capital, LLC ("EcoR1"), Oleg Nodelman and EcoR1 Capital Fund Qualified, L.P. ("Qualified Fund"). EcoR1 is the general partner and investment adviser of private funds, including Qualified Fund (the "Funds"). Mr. Nodelman is the manager and controlling owner of EcoR1. EcoR1 is filing this Form 4 for itself and Qualified Fund. The filers are filing this Form 4 jointly, but not as a group, and each expressly disclaims membership in a group within the meaning of Rule 13d-5(b) under the Securities Exchange Act of 1934. The Funds hold these securities directly for the benefit of their investors. EcoR1 may be deemed to indirectly beneficially own them as the investment adviser to the Funds. Mr. Nodelman may be deemed to indirectly beneficially own them as the control person of EcoR1. The filers disclaim beneficial ownership of the securities except to the extent of their respective pecuniary interests therein. Read SEC document |
| April 03, 2025 Filed Apr 7, 2025 18:34 UTC | Zymeworks Inc. ZYME · Entity 4458 | PurchaseCommon Stock | 120,770 | $11.84 | $1,430,170.42 |
DisclosureSEC source: 0000935836-25-000266 · ownership.xml · nonDerivative · entry 1 EcoR1 Capital, LLC · CIK 0001587114 · Director · 10% owner NODELMAN OLEG · CIK 0001454385 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Note Disclosed balance after: 17,503,336 F2 · shares: Qualified Fund purchased 113,233 of the shares purchased in this transaction. F3 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $11.8101 to $11.9123 inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each seperate price within the ranges set forth in this footnote and footnote 6. F4 · balance_after: After this transaction, Qualified Fund held 16,407,320 shares of the Issuer's Common Stock. F1 · ownership.nature: The reporting persons are EcoR1 Capital, LLC ("EcoR1"), Oleg Nodelman and EcoR1 Capital Fund Qualified, L.P. ("Qualified Fund"). EcoR1 is the general partner and investment adviser of private funds, including Qualified Fund (the "Funds"). Mr. Nodelman is the manager and controlling owner of EcoR1. EcoR1 is filing this Form 4 for itself and Qualified Fund. The filers are filing this Form 4 jointly, but not as a group, and each expressly disclaims membership in a group within the meaning of Rule 13d-5(b) under the Securities Exchange Act of 1934. The Funds hold these securities directly for the benefit of their investors. EcoR1 may be deemed to indirectly beneficially own them as the investment adviser to the Funds. Mr. Nodelman may be deemed to indirectly beneficially own them as the control person of EcoR1. The filers disclaim beneficial ownership of the securities except to the extent of their respective pecuniary interests therein. Read SEC document |
| April 02, 2025 Filed Apr 2, 2025 19:02 UTC | Zymeworks Inc. ZYME · Entity 4458 | PurchaseCommon Stock | 74,360 | $11.85 | $881,017.28 |
DisclosureSEC source: 0000935836-25-000259 · ownership.xml · nonDerivative · entry 3 EcoR1 Capital, LLC · CIK 0001587114 · Director · 10% owner NODELMAN OLEG · CIK 0001454385 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Note Disclosed balance after: 17,382,566 F6 · shares: Qualified Fund purchased 69,720 of the shares purchased in this transaction. F7 · balance_after: After this transaction, Qualified Fund held 16,294,087 shares of the Issuer's Common Stock. F1 · ownership.nature: The reporting persons are EcoR1 Capital, LLC ("EcoR1"), Oleg Nodelman and EcoR1 Capital Fund Qualified, L.P. ("Qualified Fund"). EcoR1 is the general partner and investment adviser of private funds, including Qualified Fund (the "Funds"). Mr. Nodelman is the manager and controlling owner of EcoR1. EcoR1 is filing this Form 4 for itself and Qualified Fund. The filers are filing this Form 4 jointly, but not as a group, and each expressly disclaims membership in a group within the meaning of Rule 13d-5(b) under the Securities Exchange Act of 1934. The Funds hold these securities directly for the benefit of their investors. EcoR1 may be deemed to indirectly beneficially own them as the investment adviser to the Funds. Mr. Nodelman may be deemed to indirectly beneficially own them as the control person of EcoR1. The filers disclaim beneficial ownership of the securities except to the extent of their respective pecuniary interests therein. Read SEC document |
| April 01, 2025 Filed Apr 2, 2025 19:02 UTC | Zymeworks Inc. ZYME · Entity 4458 | PurchaseCommon Stock | 48,658 | $11.60 | $564,646.90 |
DisclosureSEC source: 0000935836-25-000259 · ownership.xml · nonDerivative · entry 2 EcoR1 Capital, LLC · CIK 0001587114 · Director · 10% owner NODELMAN OLEG · CIK 0001454385 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Note Disclosed balance after: 17,308,206 F4 · shares: Qualified Fund purchased 45,622 of the shares purchased in this transaction. F5 · balance_after: After this transaction, Qualified Fund held 16,224,367 shares of the Issuer's Common Stock. F1 · ownership.nature: The reporting persons are EcoR1 Capital, LLC ("EcoR1"), Oleg Nodelman and EcoR1 Capital Fund Qualified, L.P. ("Qualified Fund"). EcoR1 is the general partner and investment adviser of private funds, including Qualified Fund (the "Funds"). Mr. Nodelman is the manager and controlling owner of EcoR1. EcoR1 is filing this Form 4 for itself and Qualified Fund. The filers are filing this Form 4 jointly, but not as a group, and each expressly disclaims membership in a group within the meaning of Rule 13d-5(b) under the Securities Exchange Act of 1934. The Funds hold these securities directly for the benefit of their investors. EcoR1 may be deemed to indirectly beneficially own them as the investment adviser to the Funds. Mr. Nodelman may be deemed to indirectly beneficially own them as the control person of EcoR1. The filers disclaim beneficial ownership of the securities except to the extent of their respective pecuniary interests therein. Read SEC document |
| March 31, 2025 Filed Apr 2, 2025 19:02 UTC | Zymeworks Inc. ZYME · Entity 4458 | PurchaseCommon Stock | 4,397 | $11.75 | $51,658.15 |
DisclosureSEC source: 0000935836-25-000259 · ownership.xml · nonDerivative · entry 1 EcoR1 Capital, LLC · CIK 0001587114 · Director · 10% owner NODELMAN OLEG · CIK 0001454385 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Note Disclosed balance after: 17,259,548 F2 · shares: Qualified Fund purchased 4,129 of the shares purchased in this transaction. F3 · balance_after: After this transaction, Qualified Fund held 16,178,745 shares of the Issuer's Common Stock. F1 · ownership.nature: The reporting persons are EcoR1 Capital, LLC ("EcoR1"), Oleg Nodelman and EcoR1 Capital Fund Qualified, L.P. ("Qualified Fund"). EcoR1 is the general partner and investment adviser of private funds, including Qualified Fund (the "Funds"). Mr. Nodelman is the manager and controlling owner of EcoR1. EcoR1 is filing this Form 4 for itself and Qualified Fund. The filers are filing this Form 4 jointly, but not as a group, and each expressly disclaims membership in a group within the meaning of Rule 13d-5(b) under the Securities Exchange Act of 1934. The Funds hold these securities directly for the benefit of their investors. EcoR1 may be deemed to indirectly beneficially own them as the investment adviser to the Funds. Mr. Nodelman may be deemed to indirectly beneficially own them as the control person of EcoR1. The filers disclaim beneficial ownership of the securities except to the extent of their respective pecuniary interests therein. Read SEC document |
| March 26, 2025 Filed Mar 27, 2025 18:53 UTC | Zymeworks Inc. ZYME · Entity 4458 | PurchaseCommon Stock | 43,848 | $12.24 | $536,857.37 |
DisclosureSEC source: 0000935836-25-000253 · ownership.xml · nonDerivative · entry 2 EcoR1 Capital, LLC · CIK 0001587114 · Director · 10% owner NODELMAN OLEG · CIK 0001454385 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Note Disclosed balance after: 17,255,151 F4 · shares: Qualified Fund purchased 41,177 of the shares purchased in this transaction. F5 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $12.2293 to $12.3537, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote. F6 · balance_after: After this transaction, Qualified Fund held 16,174,616 shares of the Issuer's Common Stock. F1 · ownership.nature: The reporting persons are EcoR1 Capital, LLC ("EcoR1"), Oleg Nodelman and EcoR1 Capital Fund Qualified, L.P. ("Qualified Fund"). EcoR1 is the general partner and investment adviser of private funds, including Qualified Fund (the "Funds"). Mr. Nodelman is the manager and controlling owner of EcoR1. EcoR1 is filing this Form 4 for itself and Qualified Fund. The filers are filing this Form 4 jointly, but not as a group, and each expressly disclaims membership in a group within the meaning of Rule 13d-5(b) under the Securities Exchange Act of 1934. The Funds hold these securities directly for the benefit of their investors. EcoR1 may be deemed to indirectly beneficially own them as the investment adviser to the Funds. Mr. Nodelman may be deemed to indirectly beneficially own them as the control person of EcoR1. The filers disclaim beneficial ownership of the securities except to the extent of their respective pecuniary interests therein. Read SEC document |
| March 25, 2025 Filed Mar 27, 2025 18:53 UTC | Zymeworks Inc. ZYME · Entity 4458 | PurchaseCommon Stock | 53,501 | $12.91 | $690,451.81 |
DisclosureSEC source: 0000935836-25-000253 · ownership.xml · nonDerivative · entry 1 EcoR1 Capital, LLC · CIK 0001587114 · Director · 10% owner NODELMAN OLEG · CIK 0001454385 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Note Disclosed balance after: 17,211,303 F2 · shares: Qualified Fund purchased 50,243 of the shares purchased in this transaction. F3 · balance_after: After this transaction, Qualified Fund held 16,133,439 shares of the Issuer's Common Stock. F1 · ownership.nature: The reporting persons are EcoR1 Capital, LLC ("EcoR1"), Oleg Nodelman and EcoR1 Capital Fund Qualified, L.P. ("Qualified Fund"). EcoR1 is the general partner and investment adviser of private funds, including Qualified Fund (the "Funds"). Mr. Nodelman is the manager and controlling owner of EcoR1. EcoR1 is filing this Form 4 for itself and Qualified Fund. The filers are filing this Form 4 jointly, but not as a group, and each expressly disclaims membership in a group within the meaning of Rule 13d-5(b) under the Securities Exchange Act of 1934. The Funds hold these securities directly for the benefit of their investors. EcoR1 may be deemed to indirectly beneficially own them as the investment adviser to the Funds. Mr. Nodelman may be deemed to indirectly beneficially own them as the control person of EcoR1. The filers disclaim beneficial ownership of the securities except to the extent of their respective pecuniary interests therein. Read SEC document |
| March 24, 2025 Filed Mar 24, 2025 17:45 UTC | Zymeworks Inc. ZYME · Entity 4458 | PurchaseCommon Stock | 22,689 | $13.08 | $296,846.99 |
DisclosureSEC source: 0000935836-25-000245 · ownership.xml · nonDerivative · entry 3 EcoR1 Capital, LLC · CIK 0001587114 · Director · 10% owner NODELMAN OLEG · CIK 0001454385 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Note Disclosed balance after: 17,157,802 F7 · shares: Qualified Fund purchased 21,307 of the shares purchased in this transaction. F8 · balance_after: After this transaction, Qualified Fund held 16,083,196 shares of the Issuer's Common Stock. F1 · ownership.nature: The reporting persons are EcoR1 Capital, LLC ("EcoR1"), Oleg Nodelman and EcoR1 Capital Fund Qualified, L.P. ("Qualified Fund"). EcoR1 is the general partner and investment adviser of private funds, including Qualified Fund (the "Funds"). Mr. Nodelman is the manager and controlling owner of EcoR1. EcoR1 is filing this Form 4 for itself and Qualified Fund. The filers are filing this Form 4 jointly, but not as a group, and each expressly disclaims membership in a group within the meaning of Rule 13d-5(b) under the Securities Exchange Act of 1934. The Funds hold these securities directly for the benefit of their investors. EcoR1 may be deemed to indirectly beneficially own them as the investment adviser to the Funds. Mr. Nodelman may be deemed to indirectly beneficially own them as the control person of EcoR1. The filers disclaim beneficial ownership of the securities except to the extent of their respective pecuniary interests therein. Read SEC document |
| March 21, 2025 Filed Mar 24, 2025 17:45 UTC | Zymeworks Inc. ZYME · Entity 4458 | PurchaseCommon Stock | 31,033 | $12.78 | $396,517.95 |
DisclosureSEC source: 0000935836-25-000245 · ownership.xml · nonDerivative · entry 2 EcoR1 Capital, LLC · CIK 0001587114 · Director · 10% owner NODELMAN OLEG · CIK 0001454385 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Note Disclosed balance after: 17,135,113 F4 · shares: Qualified Fund purchased 29,143 of the shares purchased in this transaction. F5 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $12.6895 to $12.9881 inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote with the ranges set forth in this footnote. F6 · balance_after: After this transaction, Qualified Fund held 16,061,889 shares of the Issuer's Common Stock. F1 · ownership.nature: The reporting persons are EcoR1 Capital, LLC ("EcoR1"), Oleg Nodelman and EcoR1 Capital Fund Qualified, L.P. ("Qualified Fund"). EcoR1 is the general partner and investment adviser of private funds, including Qualified Fund (the "Funds"). Mr. Nodelman is the manager and controlling owner of EcoR1. EcoR1 is filing this Form 4 for itself and Qualified Fund. The filers are filing this Form 4 jointly, but not as a group, and each expressly disclaims membership in a group within the meaning of Rule 13d-5(b) under the Securities Exchange Act of 1934. The Funds hold these securities directly for the benefit of their investors. EcoR1 may be deemed to indirectly beneficially own them as the investment adviser to the Funds. Mr. Nodelman may be deemed to indirectly beneficially own them as the control person of EcoR1. The filers disclaim beneficial ownership of the securities except to the extent of their respective pecuniary interests therein. Read SEC document |
| March 20, 2025 Filed Mar 24, 2025 17:45 UTC | Zymeworks Inc. ZYME · Entity 4458 | PurchaseCommon Stock | 73,476 | $12.93 | $949,883.03 |
DisclosureSEC source: 0000935836-25-000245 · ownership.xml · nonDerivative · entry 1 EcoR1 Capital, LLC · CIK 0001587114 · Director · 10% owner NODELMAN OLEG · CIK 0001454385 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Note Disclosed balance after: 17,104,080 F2 · shares: Qualified Fund purchased 69,000 of the shares purchased in this transaction. F3 · balance_after: After this transaction, Qualified Fund held 16,032,746 shares of the Issuer's Common Stock. F1 · ownership.nature: The reporting persons are EcoR1 Capital, LLC ("EcoR1"), Oleg Nodelman and EcoR1 Capital Fund Qualified, L.P. ("Qualified Fund"). EcoR1 is the general partner and investment adviser of private funds, including Qualified Fund (the "Funds"). Mr. Nodelman is the manager and controlling owner of EcoR1. EcoR1 is filing this Form 4 for itself and Qualified Fund. The filers are filing this Form 4 jointly, but not as a group, and each expressly disclaims membership in a group within the meaning of Rule 13d-5(b) under the Securities Exchange Act of 1934. The Funds hold these securities directly for the benefit of their investors. EcoR1 may be deemed to indirectly beneficially own them as the investment adviser to the Funds. Mr. Nodelman may be deemed to indirectly beneficially own them as the control person of EcoR1. The filers disclaim beneficial ownership of the securities except to the extent of their respective pecuniary interests therein. Read SEC document |
| March 19, 2025 Filed Mar 19, 2025 18:32 UTC | Zymeworks Inc. ZYME · Entity 4458 | PurchaseCommon Stock | 58,306 | $12.64 | $737,232.73 |
DisclosureSEC source: 0000935836-25-000239 · ownership.xml · nonDerivative · entry 3 EcoR1 Capital, LLC · CIK 0001587114 · Director · 10% owner NODELMAN OLEG · CIK 0001454385 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Note Disclosed balance after: 17,030,604 F8 · shares: Qualified Fund purchased 54,758 of the shares purchased in this transaction. F9 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $12.5029 to $12.7711, inclusive. F10 · balance_after: After this transaction, Qualified Fund held 15,963,746 shares of the Issuer's Common Stock. F1 · ownership.nature: The reporting persons are EcoR1 Capital, LLC ("EcoR1"), Oleg Nodelman and EcoR1 Capital Fund Qualified, L.P. ("Qualified Fund"). EcoR1 is the general partner and investment adviser of private funds, including Qualified Fund (the "Funds"). Mr. Nodelman is the manager and controlling owner of EcoR1. EcoR1 is filing this Form 4 for itself and Qualified Fund. The filers are filing this Form 4 jointly, but not as a group, and each expressly disclaims membership in a group within the meaning of Rule 13d-5(b) under the Securities Exchange Act of 1934. The Funds hold these securities directly for the benefit of their investors. EcoR1 may be deemed to indirectly beneficially own them as the investment adviser to the Funds. Mr. Nodelman may be deemed to indirectly beneficially own them as the control person of EcoR1. The filers disclaim beneficial ownership of the securities except to the extent of their respective pecuniary interests therein. Read SEC document |
| March 18, 2025 Filed Mar 19, 2025 18:32 UTC | Zymeworks Inc. ZYME · Entity 4458 | PurchaseCommon Stock | 113,880 | $12.65 | $1,440,855.31 |
DisclosureSEC source: 0000935836-25-000239 · ownership.xml · nonDerivative · entry 2 EcoR1 Capital, LLC · CIK 0001587114 · Director · 10% owner NODELMAN OLEG · CIK 0001454385 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Note Disclosed balance after: 16,972,298 F5 · shares: Qualified Fund purchased 106,944 of the shares purchased in this transaction. F6 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $12.3214 to $12.7045, inclusive. F7 · balance_after: After this transaction, Qualified Fund held 15,908,988 shares of the Issuer's Common Stock. F1 · ownership.nature: The reporting persons are EcoR1 Capital, LLC ("EcoR1"), Oleg Nodelman and EcoR1 Capital Fund Qualified, L.P. ("Qualified Fund"). EcoR1 is the general partner and investment adviser of private funds, including Qualified Fund (the "Funds"). Mr. Nodelman is the manager and controlling owner of EcoR1. EcoR1 is filing this Form 4 for itself and Qualified Fund. The filers are filing this Form 4 jointly, but not as a group, and each expressly disclaims membership in a group within the meaning of Rule 13d-5(b) under the Securities Exchange Act of 1934. The Funds hold these securities directly for the benefit of their investors. EcoR1 may be deemed to indirectly beneficially own them as the investment adviser to the Funds. Mr. Nodelman may be deemed to indirectly beneficially own them as the control person of EcoR1. The filers disclaim beneficial ownership of the securities except to the extent of their respective pecuniary interests therein. Read SEC document |
| March 17, 2025 Filed Mar 19, 2025 18:32 UTC | Zymeworks Inc. ZYME · Entity 4458 | PurchaseCommon Stock | 56,277 | $12.23 | $688,464.68 |
DisclosureSEC source: 0000935836-25-000239 · ownership.xml · nonDerivative · entry 1 EcoR1 Capital, LLC · CIK 0001587114 · Director · 10% owner NODELMAN OLEG · CIK 0001454385 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Note Disclosed balance after: 16,858,418 F2 · shares: Qualified Fund purchased 52,849 of the shares purchased in this transaction. F3 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $12.1287 to $12.2678 inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote with the ranges set forth in this footnote. F4 · balance_after: After this transaction, Qualified Fund held 15,802,044 shares of the Issuer's Common Stock. F1 · ownership.nature: The reporting persons are EcoR1 Capital, LLC ("EcoR1"), Oleg Nodelman and EcoR1 Capital Fund Qualified, L.P. ("Qualified Fund"). EcoR1 is the general partner and investment adviser of private funds, including Qualified Fund (the "Funds"). Mr. Nodelman is the manager and controlling owner of EcoR1. EcoR1 is filing this Form 4 for itself and Qualified Fund. The filers are filing this Form 4 jointly, but not as a group, and each expressly disclaims membership in a group within the meaning of Rule 13d-5(b) under the Securities Exchange Act of 1934. The Funds hold these securities directly for the benefit of their investors. EcoR1 may be deemed to indirectly beneficially own them as the investment adviser to the Funds. Mr. Nodelman may be deemed to indirectly beneficially own them as the control person of EcoR1. The filers disclaim beneficial ownership of the securities except to the extent of their respective pecuniary interests therein. Read SEC document |
| March 13, 2025 Filed Mar 13, 2025 19:35 UTC | Zymeworks Inc. ZYME · Entity 4458 | PurchaseCommon Stock | 468,356 | $12.48 | $5,847,237.32 |
DisclosureSEC source: 0000935836-25-000225 · ownership.xml · nonDerivative · entry 3 EcoR1 Capital, LLC · CIK 0001587114 · Director · 10% owner NODELMAN OLEG · CIK 0001454385 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Note Disclosed balance after: 16,802,141 F8 · shares: Qualified Fund purchased 439,831 of the shares purchased in this transaction. F9 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $12.26 to $12.55, inclusive. F10 · balance_after: After this transaction, Qualified Fund held 15,749,195 shares of the Issuer's Common Stock. F1 · ownership.nature: The reporting persons are EcoR1 Capital, LLC ("EcoR1"), Oleg Nodelman and EcoR1 Capital Fund Qualified, L.P. ("Qualified Fund"). EcoR1 is the general partner and investment adviser of private funds, including Qualified Fund (the "Funds"). Mr. Nodelman is the manager and controlling owner of EcoR1. EcoR1 is filing this Form 4 for itself and Qualified Fund. The filers are filing this Form 4 jointly, but not as a group, and each expressly disclaims membership in a group within the meaning of Rule 13d-5(b) under the Securities Exchange Act of 1934. The Funds hold these securities directly for the benefit of their investors. EcoR1 may be deemed to indirectly beneficially own them as the investment adviser to the Funds. Mr. Nodelman may be deemed to indirectly beneficially own them as the control person of EcoR1. The filers disclaim beneficial ownership of the securities except to the extent of their respective pecuniary interests therein. Read SEC document |
| March 12, 2025 Filed Mar 13, 2025 19:35 UTC | Zymeworks Inc. ZYME · Entity 4458 | PurchaseCommon Stock | 292,934 | $12.25 | $3,587,826.34 |
DisclosureSEC source: 0000935836-25-000225 · ownership.xml · nonDerivative · entry 2 EcoR1 Capital, LLC · CIK 0001587114 · Director · 10% owner NODELMAN OLEG · CIK 0001454385 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Note Disclosed balance after: 16,333,785 F5 · shares: Qualified Fund purchased 275,095 of the shares purchased in this transaction. F6 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $12.0008 to $12.3728, inclusive. F7 · balance_after: After this transaction, Qualified Fund held 15,309,364 shares of the Issuer's Common Stock. F1 · ownership.nature: The reporting persons are EcoR1 Capital, LLC ("EcoR1"), Oleg Nodelman and EcoR1 Capital Fund Qualified, L.P. ("Qualified Fund"). EcoR1 is the general partner and investment adviser of private funds, including Qualified Fund (the "Funds"). Mr. Nodelman is the manager and controlling owner of EcoR1. EcoR1 is filing this Form 4 for itself and Qualified Fund. The filers are filing this Form 4 jointly, but not as a group, and each expressly disclaims membership in a group within the meaning of Rule 13d-5(b) under the Securities Exchange Act of 1934. The Funds hold these securities directly for the benefit of their investors. EcoR1 may be deemed to indirectly beneficially own them as the investment adviser to the Funds. Mr. Nodelman may be deemed to indirectly beneficially own them as the control person of EcoR1. The filers disclaim beneficial ownership of the securities except to the extent of their respective pecuniary interests therein. Read SEC document |
| March 11, 2025 Filed Mar 13, 2025 19:35 UTC | Zymeworks Inc. ZYME · Entity 4458 | PurchaseCommon Stock | 320,690 | $11.49 | $3,685,850.52 |
DisclosureSEC source: 0000935836-25-000225 · ownership.xml · nonDerivative · entry 1 EcoR1 Capital, LLC · CIK 0001587114 · Director · 10% owner NODELMAN OLEG · CIK 0001454385 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Note Disclosed balance after: 16,040,851 F2 · shares: Qualified Fund purchased 301,160 of the shares purchased in this transaction. F3 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $11.115 to $11.70, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote with the ranges set forth in this footnote and footnote 6 and 9. F4 · balance_after: After this transaction, Qualified Fund held 15,034,269 shares of the Issuer's Common Stock. F1 · ownership.nature: The reporting persons are EcoR1 Capital, LLC ("EcoR1"), Oleg Nodelman and EcoR1 Capital Fund Qualified, L.P. ("Qualified Fund"). EcoR1 is the general partner and investment adviser of private funds, including Qualified Fund (the "Funds"). Mr. Nodelman is the manager and controlling owner of EcoR1. EcoR1 is filing this Form 4 for itself and Qualified Fund. The filers are filing this Form 4 jointly, but not as a group, and each expressly disclaims membership in a group within the meaning of Rule 13d-5(b) under the Securities Exchange Act of 1934. The Funds hold these securities directly for the benefit of their investors. EcoR1 may be deemed to indirectly beneficially own them as the investment adviser to the Funds. Mr. Nodelman may be deemed to indirectly beneficially own them as the control person of EcoR1. The filers disclaim beneficial ownership of the securities except to the extent of their respective pecuniary interests therein. Read SEC document |
| January 17, 2025 Filed Jan 21, 2025 22:34 UTC | Zymeworks Inc. ZYME · Entity 4458 | PurchaseCommon Stock | 19,748 | $13.87 | $273,997.58 |
DisclosureSEC source: 0000935836-25-000074 · ownership.xml · nonDerivative · entry 2 EcoR1 Capital, LLC · CIK 0001587114 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · See Note Disclosed balance after: 15,720,161 F4 · shares: Qualified Fund purchased 18,557 of the shares purchased in this transaction. F5 · balance_after: After this transaction, Qualified Fund held 14,733,109 shares of the Issuer's Common Stock. F1 · ownership.nature: The reporting persons are EcoR1 Capital, LLC ("EcoR1"), Oleg Nodelman and EcoR1 Capital Fund Qualified, L.P. ("Qualified Fund"). EcoR1 is the general partner and investment adviser of private funds, including Qualified Fund (the "Funds"). Mr. Nodelman is the manager and controlling owner of EcoR1. EcoR1 is filing this Form 4 for itself, Mr. Nodelman and Qualified Fund. The filers are filing this Form 4 jointly, but not as a group, and each expressly disclaims membership in a group within the meaning of Rule 13d-5(b) under the Securities Exchange Act of 1934. The Funds hold these securities directly for the benefit of their investors. EcoR1 may be deemed to indirectly beneficially own them as the investment adviser to the Funds. Mr. Nodelman may be deemed to indirectly beneficially own them as the control person of EcoR1. The filers disclaim beneficial ownership of the securities except to the extent of their respective pecuniary interests therein. Read SEC document |
| January 16, 2025 Filed Jan 21, 2025 22:34 UTC | Zymeworks Inc. ZYME · Entity 4458 | PurchaseCommon Stock | 121,681 | $13.89 | $1,689,540.69 |
DisclosureSEC source: 0000935836-25-000074 · ownership.xml · nonDerivative · entry 1 EcoR1 Capital, LLC · CIK 0001587114 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · See Note Disclosed balance after: 15,700,413 F2 · shares: Qualified Fund purchased 114,344 of the shares purchased in this transaction. F3 · balance_after: After this transaction, Qualified Fund held 14,714,552 shares of the Issuer's Common Stock. F1 · ownership.nature: The reporting persons are EcoR1 Capital, LLC ("EcoR1"), Oleg Nodelman and EcoR1 Capital Fund Qualified, L.P. ("Qualified Fund"). EcoR1 is the general partner and investment adviser of private funds, including Qualified Fund (the "Funds"). Mr. Nodelman is the manager and controlling owner of EcoR1. EcoR1 is filing this Form 4 for itself, Mr. Nodelman and Qualified Fund. The filers are filing this Form 4 jointly, but not as a group, and each expressly disclaims membership in a group within the meaning of Rule 13d-5(b) under the Securities Exchange Act of 1934. The Funds hold these securities directly for the benefit of their investors. EcoR1 may be deemed to indirectly beneficially own them as the investment adviser to the Funds. Mr. Nodelman may be deemed to indirectly beneficially own them as the control person of EcoR1. The filers disclaim beneficial ownership of the securities except to the extent of their respective pecuniary interests therein. Read SEC document |
| January 15, 2025 Filed Jan 15, 2025 23:12 UTC | Zymeworks Inc. ZYME · Entity 4458 | PurchaseCommon Stock | 39,029 | $14.01 | $546,671.40 |
DisclosureSEC source: 0000935836-25-000067 · ownership.xml · nonDerivative · entry 3 EcoR1 Capital, LLC · CIK 0001587114 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · See Note Disclosed balance after: 15,578,732 F6 · shares: Qualified Fund purchased 36,676 of the shares purchased in this transaction. F7 · balance_after: After this transaction, Qualified Fund held 14,600,208 shares of the Issuer's Common Stock. F1 · ownership.nature: The reporting persons are EcoR1 Capital, LLC ("EcoR1"), Oleg Nodelman and EcoR1 Capital Fund Qualified, L.P. ("Qualified Fund"). EcoR1 is the general partner and investment adviser of private funds, including Qualified Fund (the "Funds"). Mr. Nodelman is the manager and controlling owner of EcoR1. EcoR1 is filing this Form 4 for itself, Mr. Nodelman and Qualified Fund. The filers are filing this Form 4 jointly, but not as a group, and each expressly disclaims membership in a group within the meaning of Rule 13d-5(b) under the Securities Exchange Act of 1934. The Funds hold these securities directly for the benefit of their investors. EcoR1 may be deemed to indirectly beneficially own them as the investment adviser to the Funds. Mr. Nodelman may be deemed to indirectly beneficially own them as the control person of EcoR1. The filers disclaim beneficial ownership of the securities except to the extent of their respective pecuniary interests therein. Read SEC document |
| January 14, 2025 Filed Jan 15, 2025 23:12 UTC | Zymeworks Inc. ZYME · Entity 4458 | PurchaseCommon Stock | 54,500 | $13.56 | $739,265.25 |
DisclosureSEC source: 0000935836-25-000067 · ownership.xml · nonDerivative · entry 2 EcoR1 Capital, LLC · CIK 0001587114 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · See Note Disclosed balance after: 15,539,703 F4 · shares: Qualified Fund purchased 51,213 of the shares purchased in this transaction. F5 · balance_after: After this transaction, Qualified Fund held 14,563,532 shares of the Issuer's Common Stock. F1 · ownership.nature: The reporting persons are EcoR1 Capital, LLC ("EcoR1"), Oleg Nodelman and EcoR1 Capital Fund Qualified, L.P. ("Qualified Fund"). EcoR1 is the general partner and investment adviser of private funds, including Qualified Fund (the "Funds"). Mr. Nodelman is the manager and controlling owner of EcoR1. EcoR1 is filing this Form 4 for itself, Mr. Nodelman and Qualified Fund. The filers are filing this Form 4 jointly, but not as a group, and each expressly disclaims membership in a group within the meaning of Rule 13d-5(b) under the Securities Exchange Act of 1934. The Funds hold these securities directly for the benefit of their investors. EcoR1 may be deemed to indirectly beneficially own them as the investment adviser to the Funds. Mr. Nodelman may be deemed to indirectly beneficially own them as the control person of EcoR1. The filers disclaim beneficial ownership of the securities except to the extent of their respective pecuniary interests therein. Read SEC document |
| January 13, 2025 Filed Jan 15, 2025 23:12 UTC | Zymeworks Inc. ZYME · Entity 4458 | PurchaseCommon Stock | 74,125 | $13.39 | $992,874.73 |
DisclosureSEC source: 0000935836-25-000067 · ownership.xml · nonDerivative · entry 1 EcoR1 Capital, LLC · CIK 0001587114 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · See Note Disclosed balance after: 15,485,203 F2 · shares: Qualified Fund purchased 69,655 of the shares purchased in this transaction. F3 · balance_after: After this transaction, Qualified Fund held 14,512,319 shares of the Issuer's Common Stock. F1 · ownership.nature: The reporting persons are EcoR1 Capital, LLC ("EcoR1"), Oleg Nodelman and EcoR1 Capital Fund Qualified, L.P. ("Qualified Fund"). EcoR1 is the general partner and investment adviser of private funds, including Qualified Fund (the "Funds"). Mr. Nodelman is the manager and controlling owner of EcoR1. EcoR1 is filing this Form 4 for itself, Mr. Nodelman and Qualified Fund. The filers are filing this Form 4 jointly, but not as a group, and each expressly disclaims membership in a group within the meaning of Rule 13d-5(b) under the Securities Exchange Act of 1934. The Funds hold these securities directly for the benefit of their investors. EcoR1 may be deemed to indirectly beneficially own them as the investment adviser to the Funds. Mr. Nodelman may be deemed to indirectly beneficially own them as the control person of EcoR1. The filers disclaim beneficial ownership of the securities except to the extent of their respective pecuniary interests therein. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.